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CHAPTER 1 
EPISTASIS IN HUMANS: EXPECTATIONS AND CHALLENGES 
 
 
Epistasis is a phenomenon wherein the effect of a genetic variant on the phenotype is dependent 
on another genetic variant. The importance of epistasis – in terms of both prevalence, and effect 
sizes – to human health is controversial.  Evidence from model organisms suggests that epistasis 
is widespread, and accounts for a notable proportion of phenotypic variance.1,2  Similarly, 
additive genetic effects fail to fully account for the estimated heritability underlying the majority 
of human traits;3,4 however, concrete evidence for epistasis influencing complex traits in humans 
remains elusive due to both experimental and computational limitations.  Studies of epistasis in 
human have largely relied on observational studies. While the computational burden of 
performing genome-wide association studies for epistasis is no longer prohibitive for common 
variants, major statistical experimental limitations still complicate the field. In this dissertation, I 
take two approaches to address major concerns still facing the statistical study of epistasis in 
humans: a development of best practices, to ensure statistical interactions are indicative of 
biological epistasis, and then an investigation of epistasis between cis-regulatory variants 
influencing both a low-level phenotype directly tied to the nucleotide sequence – gene 
expression – and an array of complex phenotypes derived from electronic health records (EHR). 
 
The different faces of epistasis – perspectives from statistics and molecular biology 
 
The study of epistasis has taken several forms over the course of the last century, resulting in 
related but distinct definitions for the term in the fields of molecular and statistical genetics. 
William Bateson first coined the term epistasis in 19095, referring to a phenomenon wherein an 
allele at one locus is able to mask the effect of an allele at another locus.  Bateson, who was 
expanding the work of Mendel, illustrated epistasis in sweet peas: he observed that peas with 
white flowers produced peas with purple flowers in non-Mendelian ratios (9:7) when crossed 
together.6 From this, he concluded that the alleles interacted with one another to determine 
flower pigmentation. Further work has confirmed his hypothesis: these strains harbor mutations 
in two distinct genes within the enzymatic pathway responsible for processing anthocyanin, the 
pigment responsible for flower color.7 Either mutation is therefore sufficient for the production 
of white flowers. Notably, the same principles underlie coat coloration in mammals: recessive, 
loss-of-function variants in genes responsible for synthesizing melanin, a pigment, result in 
albinos.8 Thus, the molecular genetics definition of epistasis – in which an allele masks the effect 
of an allele at another locus – has been well illustrated, especially in the context of biological 
pathways. 
The idea of epistasis was then adapted by R.A. Fisher in 1918 to describe a statistical 
phenomenon: interactions.9 Mathematically, an interaction is defined as a deviation from 
additivity, which occurs when the combined effect of alleles at different loci is not equivalent to 
the sum of their individual effects.10 This is conceptually analogous to the colloquial phrase “The 
whole is greater (or less) than the sum of the parts,” and an example is provided in Figure 1. This 
type of epistatic relationship can be represented by the inclusion of interaction terms in the 
mathematical models typically used in genetic association studies. However, this is a purely 
statistical construct, and as will be discussed in Chapter 2, the existence of a statistically 
significant interaction term does not necessarily indicate there is underlying biological epistasis. 
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For the remainder of this work, I will be referring to statistical epistasis as defined by R.A. 
Fisher. 
 
 
 
 
Figure 1. An example of a statistical interaction.  In this visualization, individuals are 
stratified based on the number of minor alleles they have at two single nucleotide polymorphisms 
(SNPs). A summary of the gene expression for the individuals in each of the possible nine 
genotype combinations is provided as a boxplot. In this example, there is an increase in mean 
gene expression per minor allele of the second variant, indicating this variant is associated with 
gene expression levels independently. The first SNP has little influence on gene expression, 
except when there are two minor alleles at both loci.  This group, highlighted in green, is a 
statistical interaction as the mean increase in gene expression anticipated for the second variant is 
far exceeded when it occurs on the background of two minor alleles at the first locus. Many other 
forms of statistical interactions are possible. 
 
Epistasis is pervasive in model organisms 
 
The genetic architecture underlying a variety of both fundamental biological processes and 
complex traits has been extensively studied in in an array of model organisms due to an inability 
to experimentally investigate the same questions, due to either ethical or methodological 
limitations, in humans. Below is a survey of the study of epistasis in three of the most commonly 
used model organisms: Saccharomyces cerevisiae, or yeast; Drosphila melanogaster, or fly; and 
Mus musculus, or mouse. 
S. cerevisiae has long-served as model for discovering the genetic underpinnings of 
fundamental cellar processes, the basic principles of which are frequently shared with higher 
organisms.  As a result, several strains of yeast have previously been genotyped,11 efficient 
protocols exist to collect a variety of phenotypic data, and powerful molecular approaches, such 
as the two-hybrid cross, have already been developed to dissect the genetic underpinnings of 
traits.12  Altogether, this makes yeast an ideal species to begin the exploration of epistasis.   
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Gene expression is an ideal phenotype to begin the study of epistasis, due to several 
methodological and biological considerations. Foremost, gene expression is a low-level 
phenotype in the sense that it is closely linked to the nucleotide composition; i.e., mutations in 
promoters or enhancers can directly disrupt the binding of transcriptional machinery, thereby 
influencing transcript levels. Moreover, two high-throughput methodologies exist to ascertain the 
expression of the majority of genes simultaneously: microarrays and RNA-sequencing. This 
enables the investigation of many phenotypes simultaneously, and thus results in a more 
comprehensive representation of the types of genetic architectures possible.  Finally, and as will 
be discussed in more detail in Chapter 2, disruption of gene expression is believed to play a 
fundamental role in the development of complex disease. Consequently, understanding the 
genetic regulation of gene expression may translate into an increased knowledge of the genetic 
etiology of complex diseases pertinent to human health.  
Brem and Kruglyak13 conducted one of the first large-scale studies of epistasis, and 
capitalized on both the suitability of S. cerevisiae and the utility of gene expression.  First, they 
crossed a common laboratory yeast strain and a wild isolate.  In the recombinant offspring, they 
determined that roughly half of all genes had highly heritable expression levels, and moreover, 
almost six hundred (16%) had statistical evidence for epistasis. They determined this using a 
modified Lynch and Walsh test, which examines whether the mean expression level for a given 
transcript is the same for both the offspring and parents (as would be anticipated with additive 
genetic effects).13 To identify the specific variants underlying the epistatic effects, they 
performed an expression quantitative trait loci analysis for epistasis.  In this, a linear regression 
model was constructed for each pair of variants, in which an interaction term was included to 
represent epistasis. They identified over two hundred high-confidence statistical interactions 
between genetic variants.14  As a proof of principle that the identified interactions were 
biological phenomenon, they further investigated an interaction between genetic variants that 
appeared to regulate the expression of multiple transcripts. They engineered isogenic yeast 
strains (i.e., strains genetically identical aside from the interacting variants) and found that the 
resulting changes in gene expression levels matched the previously observed patterns for 10 of 
the 15 transcripts. These studies illustrate that, in yeast, genetic variants interact with one another 
to have non-additive effects on the expression level of at least several hundred transcripts. 
Next, Bloom et al.1 addressed whether the genetic architecture of gene expression levels 
translated to that of more complex traits. Using the same yeast cross, Bloom et al.1 investigated 
whether there was evidence for epistasis underlying twenty distinct growth-traits. They 
partitioned phenotypic variance into additive and epistatic genetic effects and found interactions 
accounted for between 2.2% and 21.2% of phenotypic variance, depending on the trait.  They 
then performed a scan for pairwise interactions, and identified several hundred interactions 
between specific variants, which accounted for roughly half of the phenotypic variance attributed 
to interaction effects.  The effect sizes of these interactions, however, were markedly reduced 
compared to those observed for additive effects. This illustrates that additive genetic effects 
likely dominate the genetic architecture for most traits; however, epistasis accounts for a notable 
proportion of phenotypic variance, largely due to large numbers of small-effect pairwise 
interactions.  
While yeast serve a critical role in better understanding the genetic principles of higher 
organisms, it is always critical to illustrate that the principles discovered generalize between 
species.  There are notable differences in the quantity and type of regulatory elements observed 
between yeast, fly, and higher level eukaryotes; namely, gene expression in yeast15–17 is largely 
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regulated by regulatory elements in close proximity to the target gene, whereas gene regulation 
in higher level eukaryotes such as fly18,19,  mouse20–22 and human20,21,23–25 is more frequently 
controlled by a combination of both proximal and distal-acting regulatory elements. Such 
striking differences in the regulatory landscape between species may critically influence the 
prevalence of epistasis, as perturbations to gene expression levels play a critical role in the 
development of complex traits pertinent to human health.  Consequently, an exploration of 
epistasis in fly and mouse is a critical step in setting expectations for the phenomenon in human.    
Epistasis has been extensively investigated in fly. This endeavor has been greatly aided 
by the D. melanogaster Genetics Reference Panel (DGRP), a repository of over 200 inbred lines 
with available whole-genome sequences and a variety of quantitative traits, including gene 
expression quantified by RNA-sequencing.26  Huang et al. used linear regression to identify both 
expression quantitative trait loci (eQTL), or variants associated with the mean transcript level, 
and variance eQTL (veQTL), or variants associated with the variance in transcript levels in the 
DGRP.27 Ultimately, they found that the vast majority of veQTL significantly interacted with a 
variant within the target gene’s cis-regulatory region to regulate the variance in gene expression; 
however this could be accounted for by confounding factors addressed in the next Chapter.27 
Moreover, genetic variants associated with complex traits in the DGRP – specifically startle 
response, starvation resistance, and chill coma recovery time – demonstrated evidence for 
epistasis; the majority of variants associated with these traits engaged in at least one significant 
interaction.2  Significant variants associated with aggressive behaviors also frequently engaged in 
epistatic relationships with other variants.28  These variants were then used to create a gene-gene 
interaction network, wherein the nodes were the genes that variants mapped to (using proximity), 
and the edges were pairwise epistatic relationships.  To validate the epistatic network, Shorter et 
al.28 examined the phenotypic effects resulting from the knockout of either one, or both, gene 
partners in two pairs of directly interacting genes and two pairs of indirectly interacting genes. 
For three of the four gene pairs examined, the effect of the single-gene knockouts did not equal 
that of the double-gene knock out, indicating evidence of epistasis. 
Consequently, an exploration of epistasis in mouse is a critical step in setting 
expectations for the phenomenon in human.   Chromosome substitution strains (CSSs) have been 
an integral component of the study of epistasis in mouse; these strains of mouse have a single 
chromosome from a donor strain on the background of a host strain. This creates a homogeneous 
genetic background that reduces the ‘noise’ in phenotypic variation, which improves statistical 
power to detect effects.29  Shao et al.30 used a complete CSS panel between two strains, wherein 
a CSS had been constructed for each chromosome, to examine the genetic architecture of 41 
blood, bone, and metabolic traits in mouse. The CSS construct enabled them to quantify the 
individual effect of each chromosome on each phenotype.  Assuming additive genetic effects, the 
cumulative effect of each chromosome should equal the observed phenotypic difference between 
the two strains used to create the CSS panel. However, for 40 of 41 traits, the cumulative effect 
was significantly greater than the parental difference. Moreover, the median discrepancy was 
quite large, with the cumulative chromosome prediction anticipating a phenotypic difference 
eight times greater than that observed.30 Thus, this study indicates that in mouse, epistasis 
between genetic variants is pervasive, with cumulatively large effect sizes for the vast majority 
of studied complex traits.  
Altogether, evidence from model organisms suggests that epistasis is pervasive for both 
low-level molecular phenotypes such as gene expression, and high-level complex traits such as 
aggressive behavior.  Studies of interactions between specific variants across multiple species 
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have demonstrated that pairwise epistasis is not a rare phenomenon.13,27,31  And while these 
pairwise interactions may have smaller effects than those observed for single variants,1 in 
aggregate they account for a notable proportion of phenotypic variance depending on the trait of 
interest.2,30 However, the approaches used to study epistasis in model organisms frequently use 
selective breeding strategies that would not be either ethical or practical to use for the study of 
epistasis in humans. Thus, while evidence from a diverse range of model organisms supports the 
idea that epistatic relationships between genetic variants influence complex phenotypes, different 
approaches must be taken to determine whether epistasis underlies complex traits in humans.  
 
Insights from GWAS: The importance of the regulatory genome 
 
Within the last decade, the genetic etiology of complex disease in humans has been interrogated 
primarily through genome-wide association studies (GWAS).32–34 Previously, the interrogation 
of the genetic underpinnings of disease relied on two major approaches: linkage studies, and 
candidate studies.35–37  Linkage studies identified genomic regions that segregated through 
families with the phenotype of interest; however, pinpointing the casual variation within these 
regions was often difficult due to limited resolution.38–40 In contrast, candidate gene studies 
targeted a specific genomic region based on a priori knowledge of its function or on the basis of 
linkage studies, but were capable of identifying specific variants associated with the 
phenotype.41,42  Due to recent technological advances, GWAS are able to combine many of the 
advantages of both of these approaches. In GWAS, millions of genetic variants genome-wide are 
rapidly interrogated for association with the phenotype, enabling both comprehensive coverage 
and the identification of comparatively narrow genomic regions.35 Moreover, as this is a 
hypothesis-free approach, GWAS has the potential to identify novel genomic loci associated 
with disease.34,35,41  
 Close to three thousand GWAS have been performed for a multitude of complex traits, 
and a striking trend has emerged: the vast majority of genetic variants associated with complex 
disease are non-protein coding.32,43 It was hypothesized that these variants were regulatory in 
nature, and influenced the expression level of gene products, rather than disrupting function of 
the gene product (i.e., protein) directly.33,43–45  The development of both microarray and RNA-
sequencing technologies in conjunction with genome-wide genetic data enabled the identification 
of variants associated with changes in gene expression, termed expression quantitative trait loci 
(eQTL).46–54 Disease-associated variants identified in GWAS are enriched not only for eQTL 
status within relevant cell types,55,56 but are additionally enriched for other signatures of 
regulatory function: DNase I hypersensitivity sites,57 enhancers,58 and transcription factor 
binding sites.57 These results indicate that the majority of common variants associated with 
complex disease influence the phenotype via alterations in gene regulation.   
 For select examples, a causal link between perturbation of gene expression levels and 
complex diseases have been demonstrated.  For example, Musunuru et al.59 demonstrated that a 
variant in a non-coding region consistently associated with myocardial infarction and its causal 
risk factor LDL-cholesterol levels created a novel transcription factor binding site. This change 
resulted in a significant difference in the regulatory potential of this sequence in reporter assays, 
and was associated with the expression of the nearby gene SORT1 in eQTL analyses. They 
demonstrated the change in Sort1 levels causally influenced LDL-cholesterol levels by both 
knocking down and overexpressing Sort1 in mice; the resulting changes in LDL-cholesterol 
levels were consistent with the direction of effect observed in humans. Thus, the disruption of 
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gene expression levels by a single nucleotide polymorphism (SNP) can result in a complex 
phenotype.  There are similar examples linking disease-associated variants to changes in gene 
expression and ultimately complex disease, indicating the disruption of regulatory elements is a 
general mechanism through which non-coding variation may influence complex traits.60–64  
Given the preponderance of evidence highlighting the importance of gene regulation in 
the etiology of complex disease, I focus on regulatory epistasis in this work. However, epistasis 
between protein-coding variants influencing protein stability65–67, protein-protein interactions68, 
and protein-DNA interactions69,70 has been documented and is reviewed within the literature.71 
 
Evidence for regulatory epistasis in humans remains elusive 
 
Evidence for regulatory epistasis within humans comes from three major sources: heritability 
studies, reporter assays of regulatory elements, and genetic association studies. Each approach 
provides unique insights into regulatory epistasis, and are reviewed below. 
The first step in understanding the genetic architecture of a trait is often a heritability 
study. There are many different forms of heritability studies; however, they all provide a 
heritability estimate, which is a single score representing the proportion of phenotypic variance 
attributable to genetic variance across the entire genome. Thus, heritability estimates have 
traditionally been used to demonstrate the trait of interest has some genetic underpinning. Since 
the advent of GWAS, they have also frequently been used to estimate what proportion of the 
overall genetic effect is accounted for by individual genetic variants associated to the trait.4 
Strikingly, even when well-powered GWAS are performed, a notable proportion of the 
anticipated genetic effect is not accounted for by the individual variants.4,72  Several potential 
explanations exist for this ‘missing heritability’ phenomenon, including epistasis as the vast 
majority of GWAS assume additive effects.4,72–74  Ultimately, heritability studies demonstrate 
that additive genetic effects do not currenty account for all the genetic heritability of a trait; 
however, they provide only indirect evidence to support the existence of epistasis. 
The principles of transcription factor binding also provide indirect evidence that cis-
regulatory epistasis is plausible. Regulatory elements such as enhancers and promoters regulate 
gene expression levels via the binding of transcription factors.  Transcription factors recognize 
specific sequence patterns, called motifs. For a recognized motif, the likelihood of the 
transcription factor binding is influenced by the multitude and relative location of additional 
motifs, highlighting the combinatorial nature of transcription factor binding.75–77 Given the 
complex relationships between transcription factors and their critical role in regulatory activity, it 
is plausible that combinations of genetic variants influencing multiple transcription factor motifs 
could have epistatic relationships with one another.  
This potential for epistasis within the cis-regulatory region has been directly investigated 
through the combination of massively parallel reporter assays and synthesized regulatory 
sequences. Kwasnieski et al. investigated the effect of genetic variation within Rhodopsin 
promoter on its regulatory function.78  They engineered over a thousand single- and double-
mutant sequences, and tested their regulatory activity in mammalian cells with cis-regulatory 
element sequencing (CRE-Seq).  CRE-Seq is a reporter assay with methodological 
improvements, such that the regulatory function of thousands of sequences can be quantified 
simultaneously.  For any given pair of variants, they were able to investigate epistasis by 
comparing the total effect of the two single-mutant sequence to that of the double-mutant 
sequence. They found that the majority of double mutants had regulatory activity levels 
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significantly different than the anticipated combined effect of the single-mutants.  Their work 
illustrates that epistasis within the cis-regulatory region is possible; however, it does not address 
how frequent epistasis is within natural populations. 
 Genetic association studies of epistasis may provide insight into how frequently epistatic 
relationships between variants occur in natural populations. Using Fisher’s definition, such 
studies typically test pairs of variants for epistasis by including both variants’ main effects and 
an interaction term between them.79–82  Two studies have directly investigated regulatory 
epistasis influencing gene expression levels using naturally observed genetic variants. Hemani et 
al. performed a genome-wide association study of epistasis wherein all possible pairs of common 
genetic variants were tested for interactions associated with the expression of each gene 
expressed in whole blood.80 They identified several hundred interactions that passed a strict 
Bonferroni multiple testing correction, and 30 interactions replicated with consistent directions 
of effect in independent datasets. Similarly, Brown et al. identified and replicated 57 interactions 
between pairs of variants that influenced gene expression levels in lymphoblastoid cell lines.81 
However, in a reply, Wood et al. demonstrated that these apparent interactions were in fact 
attributable to haplotype effects.83 Essentially, the two putatively interacting variants were 
tagging a single, causal variant through linkage disequilibrium patterns. Ultimately, all example 
of epistasis identified by Hemani et al. were consistent with this phenomenon, calling into 
question whether epistasis occurs between regulatory variants. 
Rather than investigation gene regulation directly, many other studies have investigated 
interactions between variants for a variety of complex traits in humans, including: bipolar 
disorder,84 type 1 diabetes,85 and Alzheimer’s disease.86 However, several factors complicate the 
interpretation of these results, which are discussed extensively in Chapter 2. Briefly, replication 
of interactions is notoriously difficult; many studies of epistasis either do not attempt 
replication,85 or are unable to replicate the interactions.84,86 Additionally, there are often 
alternative explanations for observed interactions such as scale effects85 or haplotype effects.83 
While only a small subset of the studies of epistasis for complex traits are mentioned here, these 
issues are so pervasive within the field that a recent review concluded that “compelling statistical 
evidence is absent for the vast majority of reported epistatic interactions.” 79  Thus, it is unclear 
how pervasive regulatory epistasis is in humans. 
 Ultimately, these results suggest that there is a great potential for regulatory epistasis: the 
transcriptional machinery acts in a combinatorial fashion, and additive genetic effects are 
insufficient to account for all of the heritability observed for complex traits.  However, 
identifying the interacting elements via statistical association faces a major challenge: lack of 
clear best practices designed to ensure statistical interactions represent biological epistasis. In 
Chapter 2, I address this by performing a genome-wide investigation of epistasis between 
variants influencing gene expression using standard quality control procedures.  I then 
systematically investigate confounding processes – both statistical and biological – that result in 
statistical interactions, but are not a product of biological epistasis.  For each, I provide at least 
one example of an interaction identified in my analysis that was produced by the confounding 
process. I then provide guidelines and recommendations to correct for the confounding process 
as either a part of quality control or through post-hoc analyses. These are critical best practice 
guidelines for future studies of epistasis. 
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Regulatory epistasis within haplotypes: evidence, difficulties, and new approaches 
 
Due to confounding issues discussed in Chapter 2, genetic association studies of epistasis 
typically focus on unlinked variants; however, there is evidence that epistasis occurs within 
haplotypes as well. Haplotypes are combinations of genetic variants that do not segregate 
independently from one another due to limited recombination. When a de novo genetic variant 
occurs, it therefore does so on a limited local background that is largely maintained; this could 
create the ideal opportunity for epistatic relationships between variants to be maintained. For 
example, deleterious coding variation might be masked by linked regulatory variation that 
reduces gene expression, and therefore maintained.  
 Three lines of evidence support the existence of regulatory epistasis within haplotypes. 
First, reporter assays illustrating regulatory epistasis investigate very small genomic regions – 50 
base pairs in the case of Kwasnieski et al.78 Due to their close physical proximity, it is likely that 
variants in these regions would be in high linkage disequilibrium (LD) with one another in 
natural populations. Secondly, Corradin et al. illustrated that multiple variants within haplotypes 
observed in natural populations can each influence the expression levels of the same gene.87  
While they did not demonstrate epistasis specifically, their findings support the hypothesis that 
nearby functional variants may occur on the same haplotype. Finally, Lappalainen et al.88 
demonstrated that rare, derived coding variants often arose on the background of common 
regulatory variants that decreased gene expression levels. This suggests that the formation of 
haplotypes may be influenced by functional relationships between variants. Thus, there is 
suggestive evidence for the existence of regulatory epistasis within haplotypes. 
While limited recombination between variants creates a unique biological environment in 
which epistasis can arise, it also creates a missing data problem that complicates its study 
through statistical association methods. Without all combinations of genetic variants, regression-
based approaches cannot accurately partition phenotypic variance into genetic components.89  
This difficulty has thus far largely prevented association-based studies of epistasis within 
haplotypes in natural populations. In Chapter 3, I leverage unique properties of admixed 
populations to investigate epistasis within haplotypes. Admixed populations arise when 
populations that have been historically reproductively isolated interbreed; for example, an 
admixture event between Europeans and West Africans beginning approximately eight 
generations ago has resulted in a two-way admixed population – African Americans.90 Admixed 
populations represent a unique opportunity to investigate epistasis within haplotypes, as the 
recombination rate at a given genomic locus differs by continental ancestry.91  Consequently, 
European haplotypes may be broken apart by African-specific recombination sites, and vice 
versa, in admixed populations. As ancestral haplotype boundaries are broken, I hypothesize that 
potentially novel combinations of genetic variants are formed that would enable the investigation 
of epistasis within the context of haplotypes.  
This phenomenon may be detected by transitions in local ancestry, or the genetic ancestry 
at a specific genomic locus. There are many methods to estimate local ancestry, such as 
RFMix,92 LAMP-LD,93,94 and HAPMIX.95  While the precise methodological approach differs 
between these methods, they follow a similar conceptual approach. First, the genetic information 
is phased, meaning that variants are placed within haplotypes, by comparing the observed 
genotypes to observed haplotypes within reference populations.96 Next, the haplotype is assigned 
an ancestry, based on which of the continental populations it is more frequent in. Using these 
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approaches, local ancestry – and transitions between ancestries – can be inferred genome-wide in 
admixed populations. 
In Chapter 3, I use transitions in local ancestry to identify genomic regions in which 
ancestry haplotypes may frequently be broken apart by recombination events. To investigate 
epistasis in these contexts, I asked whether variants interact with these downstream ancestry 
transitions to influence an array of phenotypes derived from electronic medical records.  
 
The use of electronic medical records for genetic research: opportunities and challenges 
  
The vast majority of genetic studies are designed around a specific phenotype, or set of related 
phenotypes. However, the recent construction of biobanks linking electronic health record (EHR) 
data with genetic data has greatly expanded the depth of phenotypic information available on 
individuals.97 This information is often encoded in the form of ICD-9 codes, which are 
diagnostic codes used for medical billing purposes.  ICD-9 codes cover a wide array of 
phenotypes, which they are often used as proxies for. In addition to ICD-9 codes, the EHR also 
contains lab values for many tests, which can provide quantitative endophenotypes for many 
traits of interest.  Thus, biobanks contain a wealth of both low-level, quantitative traits and 
abstractions of complex phenotypes on the same individuals, all linked to genetic information. 
 The unique properties of biobanks linking genetic information with EHR result in several 
advantages relevant to the study of epistasis. The first advantage is practical: samples are 
essentially already ascertained for many traits. This saves both the time and costs associated with 
sample ascertainment, and may enable research that would otherwise be cost-prohibitive, 
especially for younger investigators. Second, role of epistasis within the genetic architecture can 
be investigated for a broad array of phenotypes; consequently, the full spectrum of its prevalence 
can be estimated, rather than generalizing its frequency and importance within the genetic 
architecture based on a specific phenotype.  Third, the phenotype of interest does not have to be 
predetermined; instead, variants of interest can be tested for association with any phenotype 
contained within the EHR. This has enabled a new type of genetic association test – phenome-
wide association studies (PheWAS) – in which a genetic variant is systematically tested for 
association with all phenotypes.98 As discussed in Chapter 3, this is a major benefit for 
investigating epistasis within haplotypes.  Essentially, the genomic regions of interest are 
typically non-coding, and it is difficult to link these regions to a specific gene, much less a 
complex phenotype. Consequently, biobanks linking EHR and genetic data offer a unique 
opportunity to investigate the effects of epistasis across an array of phenotypes. 
PheWAS has the potential to shed light on a variety of biological mechanisms and 
functions, in addition to epistasis. For example, both Verma et al. and Ye et al. performed a 
PheWAS for a subset of stop-gain variants, and identified and replicated both known and novel 
associations.99,100 Their work helps to validate PheWAS as an approach, as they detected known 
associations, and suggests that PheWAS of stop-gain variation could be used to clinically 
characterize genes of unknown function. Simonti et al. performed a PheWAS for genetic variants 
derived from ancient admixture events with Neanderthals, linking evolutionarily intriguing 
variants of previously unknown function to phenotypes such as hypercoagulable state and 
protein-calorie malnutrition.101 Others have used PheWAS to investigate pleiotropy, a 
phenomenon wherein a genetic variant influences multiple, sometimes seemingly distinct, 
phenotypes.102,103 These studies could shed light on the shared genetic etiology of complex 
disease, and prioritize targets for drug development. Overall, PheWAS hold substantial promise 
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for both better understanding genomic regions of unknown function, and better understanding 
cross-phenotype associations. 
However, there are several issues and challenges that confront PheWAS. First, there is 
the concern that phenotypes derived from ICD-9 codes do not truly capture the phenotypes they 
purportedly represent. For example, codes may be assigned that reflect potential, rather than 
confirmed, diagnoses. This is especially true for autoimmune disorders, which frequently require 
diagnosis by a specialist.104 To easily address this concern, some researches use the ‘rule of two,’ 
requiring at least two instances of the ICD-9 code to be considered a case; in the cases of type 2 
diabetes, this has been shown to improve the positive predictive value.105,106 Still, there is 
variability in the specificity and positive predictive values of each ICD-9 code’s ability to 
represent the underlying phenotype, and performing a manual chart review for every ICD-9 code 
is not currently feasible.106 To address this concern, Denny et al. performed a PheWAS for 
known disease-genotype associations derived from the GWAS Catalog, and were able to 
replicate approximately two thirds of associations they were well-powered to detect.107 Other 
PheWAS have also replicated known associates derived from the GWAS-Catalog, illustrating 
that ICD-9 code defined phenotypes can recapitulate known associations to their analogous, 
more traditionally defined phenotypes.99,108–110 
 Multiple testing correction is an additional challenge for PheWAS. There are over 17,000 
ICD-9 codes; if each is tested, a Bonferroni threshold of 2.9x10-6 would be required to adjust for 
a single variant.105 This issue will only be further exacerbated with the transition ICD-10 codes, 
of which there are over 150,000 to improve diagnostic resolution.105  However, many of these 
codes are not actually independent from one another; for example, there are several hundred 
codes for tuberculosis, each of which specifies a unique site of infection.104  To address this 
concern, ‘PheCodes’ have been developed, which both combine redundant ICD-9 codes and 
provide exclusion criteria for putative controls.98,111 There are 1,724 PheCodes, which 
substantially reduces the number of association tests performed.104 However, PheWAS are often 
restricted a small number of variants, or tested for association with specific subset of phenotypes, 
to maintain sufficient power to detect effects. 
 Overall, PheWAS offer many advantages to better understand both the clinical 
consequences of genomic regions of unknown function, and to elucidate the shared genetic 
architecture between phenotypes.  However, the underlying data was not designed for research 
purposes and likely contains more noise than traditionally ascertained cohorts. Consequently, 
replication and careful consideration of observed genotype-phenotype associations are essential 
for PheWAS.104 
 
Challenges facing the investigation of regulatory epistasis 
 
In this work, I address two major challenges within the field of regulatory epistasis: the 
development of statistical best practices, and the investigation of epistasis within haplotypes.  In 
Chapter 2, I identify and replicate statistical interactions between cis-regulatory variants. I then 
review known sources of statistical confounding for the study of epistasis, and introduce novel 
forms of confounding. Ultimately, I develop a set of best statistical practices for the study of 
epistasis that address these confounders via additional quality control procedures or post-hoc 
analyses.  In Chapter 3, I use unique properties of admixed populations to investigate epistasis 
within the context of haplotypes.  Due to ancestry-specific recombination hotspots, haplotypes 
can be broken apart in admixed populations thereby enabling the detection of epistasis; this can 
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be detected via transitions in local ancestry. I performed a PheWAS to better understand how 
regions harboring many local ancestry transitions influenced an array of clinical phenotypes. I 
identified several interactions between variants and nearby local ancestry transitions influencing 
red blood cell traits, which serves as a proof of principle for the utility of this approach. 
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CHAPTER 2 
ARE STATISTICAL INTERACTIONS EVIDENCE FOR BIOLOGICAL EPISTASIS?1 
 
 
Introduction 
 
The importance of epistasis to the development of complex traits in humans has been highly 
contested. Despite evidence for wide-spread epistasis in model organisms,1,2,112 evidence for 
epistasis influencing complex traits in human remains elusive. This may be attributable either an 
actual lack of epistasis in humans, the inherent inability to tightly control a variety of factors 
when studying phenotypes in humans, or the fact that most phenotypes studied are several steps 
removed from the underlying biological processes that influence them. These last two 
explanations are methodological limitations that make it unclear whether the lack of observed 
epistasis in humans is a true feature of the genetic architecture, or if epistasis is simply much 
more difficult to observe outside experimental systems.  
Human-derived cell lines, while a proxy for primary tissue, provide a unique opportunity 
to investigate epistasis. Like model systems, the environment for cell lines can be tightly 
controlled, and moreover, comprehensive genetic and gene expression data can readily be 
collected by high-throughput methodologies. Gene expression is an ideal phenotype to study 
epistasis for a variety of reasons. First, the genetic architecture underlying thousands of genes’ 
expression can be investigated simultaneously with either microarray or RNA-sequencing, 
meaning that the full spectrum of epistasis is likely to be captured.   Secondly, the molecular 
mechanisms that drive gene expression are directly tied to the nucleotide sequence itself: 
transcription factors recognize and bind motif sequences to regulate gene expression, and 
disruption of these nucleotide sequences can alter expression levels.59 Also, the regulation of 
gene expression is known to involve complex molecular interactions among transcription factors 
and regulatory sequences, and experimental maps of chromatin looping and transcription factor 
binding enable biological interpretations for observed statistical interactions.25,113 Finally, the 
study of gene expression is directly relevant to complex disease: the vast majority of variants 
identified in genome-wide association studies are non-protein coding. Thus it is presumed that 
the disruption of gene regulation is causally involved in the development of many common 
diseases.43,114 In several instances, it has been shown that single nucleotide variants regulate gene 
expression by altering the function of regulatory elements, and that these altered gene expression 
profiles result in clinical phenotypes.59,61 By better understanding the genetic control of gene 
expression, I may therefore better understand the genetic architectures underlying complex 
disease. 
Genetic variants associated with gene expression levels – termed expression quantitative 
trait loci (eQTL) – have been studied extensively in primary human tissue and in cell lines. In 
many eQTL analyses, a gene-based approached is taken wherein variants within the cis-
regulatory region for a given gene are tested for association with its expression. Until recently, 
the number of association tests required to perform a similar genome-wide association test for 
interactions was not computationally feasible. However, advances in computational power are 
                                                        
1 Adapted from Fish et al., Are Interactions between cis-Regulatory Variants Evidence for 
Biological Epistasis or Statistical Artifacts?, The American Journal of Human Genetics (2016), 
http://dx.doi.org/10.1016/j.ajhg.2016.07.022 
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continually diminishing this barrier and two genome-wide studies of epistasis have identified 
replicating interactions.80,81 The validity of these interactions, however, was questioned when it 
was demonstrated that through complex linkage disequilibrium (LD) patterns, these putative 
interactions could tag single variant eQTL.83 In such cases, the genotypes at the two putatively 
interacting loci together were highly informative of the genotype at single variant eQTL; 
consequently, they were identified as statistically interacting, although this relationship 
disappears when the effect of the single variant eQTL is conditioned on.  Notably, all of the 
interactions identified in prior studies were either no longer significant or were strongly 
attenuated when the effects of additional cis-eQTL were considered. This illustrates that, 
compared to single-locus analyses, the statistical models used to detect epistasis are subject to 
novel confounding factors, which are rarely addressed in studies of epistasis.  
In this study, I investigate whether evidence for epistasis within the cis-regulatory region 
in humans persists after systematically accounting for technical, statistical, and biological 
confounding factors. I performed a targeted investigation of interactions regulating gene 
expression levels in human lymphoblastoid cell lines (LCLs): the analysis was restricted to 
nominal eQTL within the target gene’s cis-regulatory region (p<0.05) to drastically reduce the 
number of association tests performed1,115 while retaining the genomic regions most likely to 
harbor pertinent regulatory elements. Few genes showed evidence of epistasis (165 of 11,465 
genes tested), although multiple interactions were often detected for the same gene. A total of 
1,119 interactions were identified, many of which replicated in an independent dataset (90 of 803 
possible).  I then investigated confounding factors – technical (variants within probe binding 
sites, ceiling/floor effect), statistical (missing genotype combinations, population stratification), 
and biological (haplotype effects, tagging cis-eQTL) – that provide alternative, more 
parsimonious explanations than biological epistasis. Ultimately, each of the interactions 
identified could be accounted for by an alternative mechanism, suggesting that the majority of 
statistical interactions identified without accounting for confounding factors are spurious 
associations. Many of these confounding factors are inherent to the statistical models used, and 
will therefore generalize to other phenotypes; consequently, the analytic framework of this study 
will be of use to many future studies of statistical epistasis. 
 
Subjects and methods 
 
Genotyping and gene expression data 
 
The discovery dataset was comprised of individuals ascertained as part of the International 
HapMap Project, PhaseI+II,116 which consisted of 210 unrelated individuals with genome-wide 
genotyping data (Phase I+II, release 24). For each of these individuals, Stranger et al. collected 
and normalized gene expression levels from immortalized LCLs using the Sentrix Human-6 
Expression Bead Chip, v1.53 All probes with a HapMap SNP underlying the expression probe 
were removed from analysis.53 I applied a population normalization procedure, described by 
Veyrieras et al.,117 to the gene expression values that such that the expression of each gene within 
each population followed a normal distribution. This removed population-level differences in 
gene expression, which enabled us to combine all ethnicities in our analysis.  Our replication 
dataset consists of 232 unrelated individuals from the 1000 Genomes Project (1KG), for whom 
gene expression in LCLs was available. These individuals had been sequenced at low coverage 
as part of the 1KG Project;118 I used genetic data from phase I, version 3. Stranger et al. also 
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collected and normalized gene expression levels in LCLs for these individuals using Illumina 
Sentrix Human-6 Expression BeadChip, v2.54 I applied the same population normalization 
procedure 117 to these data. Both the discovery and replication dataset are multiethnic; the sample 
composition by ethnicity is shown in Table 1. 
Two additional replication datasets were used to investigate a promising interaction. The 
first consisted of 283 European-descent individuals from the Genotype-Tissue Expression 
(GTEx) Project, for whom gene expression in whole blood was assessed by RNA-sequencing.119 
Genotype data for these individuals was collected on both the HumanOmni5-Quad Array and the 
Infinium Exome Chip, and then imputed to 1KG.119 The second dataset consisted of brain 
samples from autopsied European-descent individuals in the Mayo Late Onset Alzhemier’s 
Disease Consortium.120 These individuals were genotyped on the Illumina HumanHap300-Duo 
Genotyping Beadchip and gene expression was collected using the Illumina Whole-Genome 
DASL HT BeadChip.120 370 individuals had expression data available from cerebellum, and 385 
had expression in the temporal cortex.  
 
 
Analysis Total  
Sample Size 
Ethnicity 
CHB CEU GIH JPT LWK MXL MKK YRI 
Discovery 210 45 60 - 45 - - - 60 
Replication  232 34 - - 35 80 38 - 45 
 
Table 1. Dataset Composition by Ethnicity. The number of individuals of each ethnicity (1KG 
abbreviations) in the discovery and replication analyses.  
 
Generating SNP pairs for interaction testing 
 
To generate SNP-pairs for each gene, I first identified all common SNPs within the gene’s cis-
regulatory region. To be considered common, variants had to have a MAF > 5% when all 
ethnicities were combined. Based on cis-eQTL analyses,117 the cis-regulatory region was defined 
as starting 500 kb upstream of the gene’s start and ending 500 kb downstream of the gene’s stop 
(including the gene itself); gene boundaries were taken from ENSEMBL. Previously, these 
variants were individually tested for association with the gene’s expression level in the discovery 
dataset by Veyrieras et al.117 Based on this analysis, I filtered out SNPs whose marginal effects 
were not nominally associated with gene expression (excluded p > 0.05), under the hypothesis 
that nominally associated variants may represent weak marginal effects from a true underlying 
interaction. I then considered all possible SNP-pairs amongst the remaining variants. Once this 
was done for each gene, over 21 million SNP-pairs were generated for interaction testing.  
 
Identifying significant interactions 
 
Each SNP pair was tested for interactions significantly associated with the expression of the gene 
for which it was generated.  The below interaction model (Equation 1)121 was used, which 
contains additive and dominant effects for each variant and all four possible interaction terms in 
order to ensure that variance is properly partitioned across the genetic terms.  
𝑦 = 𝜇 + 𝑎1𝑥1 + 𝑑1𝑧1 + 𝑎2𝑥2 + 𝑑2𝑧2 + 𝑖𝑎𝑎𝑥1𝑥2 + 𝑖𝑎𝑑𝑥1𝑧2 + 𝑖𝑑𝑎𝑧1𝑥2 + 𝑖𝑑𝑑𝑧1𝑧2 + 𝑃𝐶1−3 
(Equation 1) 
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where y represents gene expression, 𝑥1 and 𝑥2 use additive encoding to represent the genotype at 
SNP A and SNP B respectively, 𝑧1 and 𝑧2 use Cordell’s 
121 dominant encoding to represent the 
genotype at SNP A and B respectively, 𝑎1 and 𝑑1 are estimated coefficients representing the 
additive and dominant effects of SNP A, 𝑎2 and 𝑑2 are estimated coefficients representing the 
additive and dominant effects of SNP B, and 𝑖𝑎𝑎, 𝑖𝑎𝑑, 𝑖𝑑𝑎 and 𝑖𝑑𝑑 are estimated coefficients 
representing both additive and dominant interaction effects.   The top three principal components 
were also included as covariates (𝑃𝐶1−3). To determine the significance of interactions, this 
model was compared to a reduced model lacking the four interaction terms using a likelihood 
ratio test (LRT) (Equation 2).  
𝑦 = 𝜇 + 𝑎1𝑥1 + 𝑑1𝑧1 + 𝑎2𝑥2 + 𝑑2𝑧2 + 𝑃𝐶1−3   (Equation 2) 
This test was implemented using the program INTERSNP.122 I calculated an FDR of 5% using 
the qvalue package in R.123 
 
Identification of representative interaction eQTL models for distinct pairs of interacting genomic 
loci 
 
Some interaction eQTL (ieQTL) models identified in the discovery analysis were redundant due 
to LD. For two ieQTL models to be considered redundant, each SNP within one significant 
ieQTL model had to be in high LD (r2 ≥ 0.9) with a SNP within the second ieQTL model, and 
vice versa.  By using this criterion, the pairs were effectively correlated at r2 ≥ 0.8, the threshold 
typically used for tag-SNP selection. Redundant ieQTL models were grouped together. The 
model with the most significant LRT p-value in the discovery analysis was used to represent the 
entire group in most analyses, so that each pair of interacting genomic loci was equally 
represented.  
 
Statistical power estimation 
 
We performed simulation analyses to determine the power to identify interactions.  I first 
randomly sampled a set of 20,000 SNP-pairs having all nine genotype combinations present, and 
then used the observed genetic data to simulate gene expression values. I simulated gene 
expression values based on the observed genotypes, the actual additive and dominant main 
effects for each of the two interacting variants, an error term drawn from a standard normal 
distribution, and embedded interaction terms of varying strength.  
To properly represent the main effects of the variants, I used βs for the additive and 
dominant terms for each variant reflecting the actual effects within our dataset.  I used the 
following model (Equation 3): 
𝑦 = 𝜇 + 𝑎1𝑥1 + 𝑑1𝑧1 + 𝑃𝐶1−3 (Equation 3) 
where y represents gene expression, uses 𝑥1 additive encoding to represent the genotype for the 
variant, 𝑧1 uses Cordell’s 
121 dominant encoding to represent the genotype, and the top three 
principal components were included as covariates (PC1-3). 
I then determined the effect size for the interaction terms. There are four interaction terms 
in the model: additive by additive (𝑖𝑎𝑎); additive by dominant; dominant by additive; and 
dominant by dominant. The 𝑖𝑎𝑎 term is significant in all significant interaction models identified 
in the actual discovery analysis, whereas the other terms are not – these terms are included so 
that phenotypic variance is appropriately partitioned between genetic components. Consequently, 
these three interaction terms were treated as nuisance variables when simulating gene expression 
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values; their βs were drawn from a normal distribution (mean = 0, standard deviation = 0.03). I 
used the effect sizes of cis-eQTL (p < 5.0 x 10-8) in our analysis to establish a ‘moderate’ 
anticipated effect size (cis-eQTL median: β=0.771) and a ‘high’ anticipated effect size (cis-eQTL 
75th percentile: β=0.908). These βs are well within the range of observed effect sizes for 
significant interactions (𝑖𝑎𝑎 median: β = 0.65 and 𝑖𝑎𝑎 max: β = 2.57). I then simulated gene 
expression data for each of the two effect sizes for each pair of SNPs.  
Next, I performed the same LRT used in the discovery analysis to identify significant 
interactions. All interactions with p-values below the FDR=5% threshold (p ≤ 1.328x10-5) were 
considered significant. I then repeated this process 10 times using the same 20,000 pairs of 
variants. In each of these ten iterations, power was calculated as the total number of pairs found 
to have a significant interaction divided by the total number of simulated interactions tested.  
 
Variants within the probe binding site  
 
To determine if variants were within the probe binding locations, I first used BLAT to identify 
the probe binding location in hg19 coordinates. Some probes returned multiple hits; 
consequently, I filtered the binding sites (binding sites had to be on the same chromosome as the 
gene, have a length > 30 base pairs, and an identity score > 95%) to identify unique binding 
locations. I then exclusively looked within a subset of our discovery dataset with sequencing data 
in the 1KG Project (n=174) to determine if there were any variants within binding sites that 
might confound the interaction analysis. 
 
Ceiling/floor effect  
 
Microarrays have a limited dynamic range that is not able to capture the extremes of gene 
expression. If the combined additive effect of two variants exceeds the threshold of detection, 
their apparent combined effect will be less than the sum of their individual effects. Thus, they 
may be spuriously identified as interacting. If this occurs, there will be a characteristic pattern of 
βs: the main effects for variants will be in the same direction, and the interaction term β will be 
in the opposite direction. I looked for this characteristic pattern to determine an upper bound of 
the prevalence of the ceiling/floor effect within our results. First, I identified the significant 
variables (β±SE could not contain zero) in the model.  All interactions were then categorized as 
having 0, 1, or 2 SNPs with a significant main effect - either additive or dominant main effects 
counted; if both additive and dominant main effects were significant for the same variant, the one 
with the largest effect size was used to represent the main effect.  For interactions where both 
variants had at least one significant main effect, I determined whether or not they had a 
concordant direction of effect. For those pairs with concordant directions of effect, I compared 
the significant interaction term with the largest absolute effect size to determine if it was 
discordant with the main effects. If this was the case, the interaction had a pattern consistent with 
a ceiling/floor effect, and was not considered clear evidence for epistasis. 
 
Population specific cis-eQTL  
 
Population-specific cis-eQTL can confound the interaction analysis, even though gene 
expression values were population normalized and the top three PCs were included as covariates. 
To investigate this, I first stratified the discovery dataset by each of the three ethnicities (CEU, 
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YRI, CHB+JPT), and tested each interaction for significance, using the same methodology. For 
interactions that were not significant (p < 0.05) in any of the populations, I determined if the 
interacting variants were population-specific cis-eQTL using Equation 3. Variants with 
nominally significant (p < 0.05) main effects were considered cis-eQTL. If a variant was 
identified as a cis-eQTL in only a subset of populations, it was considered population-specific.  
 
Conditional cis-eQTL analysis 
 
To determine if ieQTL pairs were tagging a cis-eQTL as suggested by Wood et al.,83 I first 
identified all nominal cis-eQTL (p < 0.05) for genes with significant ieQTL. To identify all 
nominal cis-eQTL, I used a subset of the discovery analysis individuals (n=174) who were also 
sequenced as part of the 1KG Project.118 I used the called genotypes from Phase III, v5. The 
same gene expression data previously described for the discovery set was used. Within this 
subset, I performed a single-marker cis-eQTL analysis for each common variant (MAF > 5%) 
within the cis-regulatory region using Equation 4: 
𝑦 = 𝜇 + 𝑎1𝑥1 + 𝑃𝐶1−3 (Equation 4) 
where y represents gene expression, 𝑥1 uses additive encoding to represent the genotype for the 
variant, and the top three principal components were included as covariates (PC1-3). Variants 
with nominal significant (p < 0.05) main effects were considered cis-eQTL. 
 
To determine if any of these cis-eQTL could account for the interaction, I created all 
pairs of cis-eQTL and ieQTL for the same gene. I incorporated each cis-eQTL into each 
interaction model (Equation 5) as shown below.  
𝑦 = 𝜇 + 𝑎1𝑥1 + 𝑑1𝑧1 + 𝑎2𝑥2 + 𝑑2𝑧2 + 𝑎3𝑥3 + 𝑑3𝑧3 + 
𝑖𝑎𝑎𝑥1𝑥2 + 𝑖𝑎𝑑𝑥1𝑧2 + 𝑖𝑑𝑎𝑧1𝑥2 + 𝑖𝑑𝑑𝑧1𝑧2 + 𝑃𝐶1−3 
  (Equation 5) 
where y represents gene expression, 𝑥1 and 𝑥2 use additive encoding to represent the genotype at 
interacting SNPs A and B respectively, 𝑧1 and 𝑧2 use Cordell’s dominant encoding to represent 
the genotype at interacting SNPs A and B respectively, 𝑎1 and 𝑑1 are estimated coefficients 
representing the additive and dominant effects of SNP A, 𝑎2 and 𝑑2 are estimated coefficients 
representing the additive and dominant effects of SNP B, and 𝑖𝑎𝑎, 𝑖𝑎𝑑 , 𝑖𝑑𝑎 and 𝑖𝑑𝑑 are estimated 
coefficients representing both additive and dominant interaction effects.  The main effect of the 
cis-eQTL is represented with additive encoding by 𝑥3 and with dominant encoding by 𝑧3; the 
estimated coefficients corresponding to the main effects are 𝑎3 and 𝑑3 respectively. The top three 
principal components were also included as covariates (PC1-3). I then performed a LRT 
comparing this model to a reduced model lacking the interaction terms (Equation 6).  
 
𝑦 = 𝜇 + 𝑎1𝑥1 + 𝑑1𝑧1 + 𝑎2𝑥2 + 𝑑2𝑧2 + 𝑎3𝑥3 + 𝑑3𝑧3 + 𝑃𝐶1−3          (Equation 6) 
 
If the LRT p-value of an interaction was nominally significant (p < 0.05) for all conditional 
analyses, I considered this evidence that the interaction and cis-eQTL represented independent 
signals. 
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Results 
 
Discovery and replication of genetic interactions that impact gene expression levels 
   
We identified interactions between nominal cis-eQTL that were significantly associated with 
gene expression levels. Our analysis was conducted using 210 individuals from the HapMap 
Project, Phase I+II, on whom both genotyping116 and gene expression data within LCLs53 were 
available. A population normalization procedure was applied to the gene expression data, so that 
there were no systematic differences between populations.117 The overall workflow for the 
analysis is shown in Figure 2. For each gene with expression data (n=11,465), I identified 
common SNPs (global MAF > 5%) within its cis-regulatory region, defined as 500 kb upstream 
to 500 kb downstream of the gene.  To increase power, I only considered variants nominally 
associated with the gene’s expression (p < 0.05) in a single-marker analysis.117 I analyzed all 
pairwise combinations of these variants for each gene, resulting in over 21 million SNP pairs. I 
then performed a likelihood ratio test (LRT) comparing a full model, which contains the top 
three PCs, main effects, and interaction terms, to a reduced model, containing only the covariates 
and main effects, to determine which interactions significantly improved model fit.121 Given the 
large number of correlated tests, I controlled the false discovery rate (FDR) at 5% (p ≤ 1.328x10-
5) across p-values from all LRT performed.123   
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Figure 2. Workflow used to identify and group ieQTL. In the discovery analysis, nominally 
significant cis-eQTL (denoted by triangles) were paired together and tested for interactions 
significantly associated with gene expression levels (denoted by arcs). The within-pair LD was 
then calculated (Figure 3), and interactions composed of variants in modest LD (r2 > 0.6) with 
one another were removed from the remainder of the analysis. Some of the remaining 
interactions represented the same pair of interacting genomic loci (Figure 4), and were 
partitioned into distinct groups (denoted by the arc color). For two interactions to be grouped 
together, each SNP within one significant ieQTL model had to be in high LD (r2 ≥ 0.9) with a 
SNP within the second ieQTL model, and vice versa.  
 
 
An objective of this analysis is to characterize how frequently epistasis occurs; therefore, 
I next performed a power analysis to determine our ability to detect interactions in this dataset.  
First, I randomly sampled a set of 20,000 SNP-pairs tested in this analysis. Then, I simulated 
gene expression values using the observed genotypes and the observed main effect for each of 
the variants. I then imbedded an interaction effect into the simulated gene expression values, 
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using both a moderate and large effect size, which were derived from the observed cis-eQTL 
effect sizes in this dataset. Assuming moderate and large effect sizes respectively, I had 21.6% - 
55.3% and 44.3% – 78.9% power to detect interactions between high-frequency variants (MAF 
0.2 – 0.5) in low LD with one another (Table 2). Thus, many potential examples of epistasis 
within the cis-regulatory region may not have been detected by this analysis, especially for low-
frequency variants or those in high LD with one another. 
 
 
Low LD (r2 < 0.05) 
MAF Range Percentage Effect Size 
Variant 1 Variant 2 Moderate Large 
0.05 <= MAF < 0.1 0.05 <= MAF < 0.1 0.02 0.0 ± 0.0 3.3 ± 10.5 
0.1 <= MAF < 0.2 0.22 2.0 ± 2.1 5.5 ± 1.9 
0.2 <= MAF < 0.3 0.55 3.5 ± 1.1 9.5 ± 2.4 
0.3 <= MAF < 0.4 0.87 5.5 ± 1.5 12.4 ± 3.0 
0.4 <= MAF <= 0.5 1.11 4.3 ± 1.1 11.9 ± 1.6 
0.1 <= MAF < 0.2 
 
0.1 <= MAF < 0.2 1.04 5.7 ± 1.4 16.7 ± 3.2 
0.2 <= MAF < 0.3 5.30 10.8 ± 1.1 25.8 ± 0.6 
0.3 <= MAF < 0.4 6.79 14.9 ± 1.2 33.3 ± 1.1 
0.4 <= MAF <= 0.5 8.16 16.2 ± 1.0 36.2 ± 1.1 
0.2 <= MAF < 0.3 
 
0.2 <= MAF < 0.3 4.47 21.6 ± 1.4 44.3 ± 1.2 
0.3 <= MAF < 0.4 10.59 30.9 ± 0.6 57.6 ± 1.3 
0.4 <= MAF <= 0.5 11.01 35.8 ± 0.7 62.7 ± 1.0 
0.3 <= MAF < 0.4 
 
0.3 <= MAF < 0.4 5.23 44.3 ± 1.0 71.1 ± 0.9 
0.4 <= MAF <= 0.5 10.58 50.3 ± 0.6 75.5 ± 0.8 
0.4 <= MAF <= 0.5 0.4 <= MAF <= 0.5 4.75 55.3 ± 1.9 78.9 ± 0.6 
 
 
Moderate LD (0.05 <= r2 < 0.3) 
MAF Range Percentage Effect Size 
Variant 1 Variant 2 Moderate Large 
0.05 <= MAF < 0.1 0.05 <= MAF < 0.1 0.04 0.0 ± 0.0 1.4 ± 4.5 
0.1 <= MAF < 0.2 0.32 2.4 ± 1.8 4.9 ± 2.7 
0.2 <= MAF < 0.3 0.21 2.7 ± 2.5 6.6 ± 2.8 
0.3 <= MAF < 0.4 0.04 1.4 ± 4.3 4.3 ± 9.6 
0.4 <= MAF <= 0.5 0.02 3.3 ± 10.0 0.0 ± 0.0 
0.1 <= MAF < 0.2 
 
0.1 <= MAF < 0.2 0.86 4.2 ± 1.8 10.4 ± 1.9 
0.2 <= MAF < 0.3 1.88 7.6 ± 1.5 19.8 ± 1.7 
0.3 <= MAF < 0.4 1.43 10.2 ± 1.2 24.6 ± 2.9 
0.4 <= MAF <= 0.5 0.86 11.9 ± 1.8 31.2 ± 2.9 
0.2 <= MAF < 0.3 
 
0.2 <= MAF < 0.3 1.62 14.6 ± 0.7 32.1 ± 2.0 
0.3 <= MAF < 0.4 3.40 20.4 ± 1.7 42.5 ± 1.7 
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0.4 <= MAF <= 0.5 3.34 22.5 ± 1.7 46.2 ± 1.5 
0.3 <= MAF < 0.4 
 
0.3 <= MAF < 0.4 2.18 25.9 ± 1.5 52.5 ± 2.4 
0.4 <= MAF <= 0.5 5.24 31.0 ± 0.8 56.0 ± 1.1 
0.4 <= MAF <= 0.5 0.4 <= MAF <= 0.5 2.85 35.2 ± 1.7 61.6 ± 2.2 
 
High LD (0.3 <= r2 < 0.6) 
MAF Range 
Percentage 
Effect Size 
Variant 1 Variant 2 Moderate Large 
0.05 <= MAF < 0.1 0.05 <= MAF < 0.1 0.01 0.0 ± 0.0 0.0 ± 0.0 
0.1 <= MAF < 0.2 0.03 2.0 ± 6.0 2.0 ± 6.3 
0.2 <= MAF < 0.3 0.00   -   - 
0.3 <= MAF < 0.4 0.00   -   - 
0.4 <= MAF <= 0.5 0.00   -   - 
0.1 <= MAF < 0.2 
 
0.1 <= MAF < 0.2 0.20 1.0 ± 1.2 2.5 ± 2.4 
0.2 <= MAF < 0.3 0.29 2.1 ± 1.5 7.1 ± 3.6 
0.3 <= MAF < 0.4 0.02 0.0 ± 0.0 0.0 ± 0.0 
0.4 <= MAF <= 0.5 0.00   -   - 
0.2 <= MAF < 0.3 
 
0.2 <= MAF < 0.3 0.65 3.1 ± 0.9 12.2 ± 2.4 
0.3 <= MAF < 0.4 0.67 6.0 ± 2.1 17.1 ± 2.1 
0.4 <= MAF <= 0.5 0.11 7.3 ± 4.2 18.6 ± 10.2 
0.3 <= MAF < 0.4 
 
0.3 <= MAF < 0.4 0.82 7.8 ± 2.1 17.4 ± 3.9 
0.4 <= MAF <= 0.5 1.11 10.1 ± 2.1 22.9 ± 3.5 
0.4 <= MAF <= 0.5 0.4 <= MAF <= 0.5 1.18 9.8 ± 1.7 24.9 ± 3.1 
 
Table 2. Power to Detect Interactions by MAF and LD. Power to detect interactions is 
contingent upon both the MAF of the two variants and the LD between the variants. To calculate 
power, I randomly selected 20,000 pairs of variants tested in this analysis and simulated gene 
expression values with interaction effects at a moderate (median β of cis-eQTLs; β = 0.771) and 
a large (75th percentile β of cis-eQTLs; β = 0.908) effect size (Methods). I then binned 
interactions according to their MAF and LD, and calculated power as the number of significant 
interactions divided by the total number of interactions within each bin.  I repeated this process 
ten times, and computed the mean power and its standard deviation across all 10 runs for each 
bin, which is reported here. For each bin, I also report the percentage it accounted for of the 
20,000 interactions. 
 
 
LD between variants complicates the interpretation of the interaction models. I addressed 
two types of LD in significant interaction models: within-pair LD, defined as the LD between the 
variants in the same interaction model, and between-pair LD, defined as the LD between variants 
in different interaction models. Modest within-pair LD indicates the variants may be identifying 
a haplotype, which could carry a single variant that is actually driving the association with gene 
expression. Wood et al. have demonstrated that even very stringent LD-pruning thresholds (r2 > 
0.1 or D’ > 0.1) are insufficient to protect against confounding by cis-eQTL,83 therefore I 
adopted a two-stage strategy to address this concern. First, I removed all pairs with variants in 
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modest LD with one another (r2 > 0.6) from the remainder of the analysis (median r2 between 
remaining pairs of interacting variants was 0.06, Figure 3).  I then directly tested for confounding 
by cis-eQTL in a later analysis. Ultimately, 5,439 interaction models were both significant and 
passed the within-pair LD filtering criteria; they were significantly associated with the 
expression of 165 unique genes, which are provided in Fish et al.’s124 Supplemental Table 2.  I 
then calculated between-pair LD, or the correlation of variants in different interaction models. 
Highly correlated interaction models were grouped together (Methods; Figure 2) because they 
likely represent the same pair of interacting genomic loci, as evidenced by their very similar 
statistical models (Figure 4). The 5,439 interaction models represented 1,119 pairs of interacting 
genomic loci (Fish et al.’s124 Supplemental Table 2). The interaction model with the most 
significant p-value in the discovery analysis was selected to represent the entire group in all 
subsequent analyses, unless specifically stated otherwise, to ensure that each pair of interacting 
genomic loci was equally represented. 
 
 
Figure 3. Linkage disequilibrium between interacting variants.  I calculated LD between 
interacting variants using both r2 and D’ to determine if they were on the same haplotype. 
Interactions between variants in modest LD (r2 > 0.6) had been removed from all stages of the 
analysis, and hence are not shown here.  
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Figure 4. Redundant SNP-pairs have very similar parameter estimates. I grouped together 
all pairs of interacting SNPs (n=5,439) identified as being redundant through LD measures. For 
each group, I identified all terms that were significant in at least one of the associated 
interactions (p < 0.05). I extracted the βs for these significant terms from all interactions within 
the group. I then calculated the standard deviation of the βs for each significant term within each 
group to determine how similar the parameter estimates were across all interactions in the same 
group. The distribution of these standard deviations, categorized by type of variable, is shown 
above. 
 
 
Next, I performed a replication analysis using an independent dataset of 232 unrelated 
individuals from the 1KG Project who had both whole-genome sequencing 118 data and gene 
expression levels in LCLs54 available. All ieQTL composed of variants that were common (MAF 
> 5%) and had available genotyping data were tested for significant interactions with the same 
procedure used in the discovery analysis. Of the 803 ieQTL tested, 363 had p-values < 0.05 and 
90 passed a Bonferroni multiple testing correction for all tests performed in the replication 
analysis.  
 
 Many factors confound interaction testing 
 
Statistical interactions can be produced by a variety of factors other than biological epistasis, 
including technical artifacts, statistical artifacts, and LD artifacts driven by other biological 
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processes. Technical artifacts are caused by the limitations of the data itself; for instance, 
limitations in the dynamic range of measureable gene expression can result in interactions being 
identified through the ceiling/floor effect.  Statistical artifacts can result in an incorrect inference 
from a statistical model; for example, when there are population-level differences in the 
phenotype, analyzing multiple ethnicities together can produce spurious associations due to 
population stratification. Technical and statistical artifacts are especially troubling since they are 
unlikely to represent a real biological association between the loci and phenotype. Other 
biological phenomena, namely haplotype effects and cis-eQTL effects, can be captured by 
interaction analyses due to LD patterns. I investigated whether the observed 1,119 significant 
ieQTL models from the discovery analysis could be explained by each of these phenomena.  
 
Some statistical interactions are consistent with confounding by technical limitations 
 
The gene expression data used in this analysis was collected using microarrays. Microarray 
technology has a limited dynamic range, meaning that the upper and lower bound on the level of 
gene expression that microarrays can detect does not cover the full range observed in nature.  
If the combined effect of two variants behaving additively exceeds the detectable limit, their 
individual effects will not be fully captured as they hit the maximum (i.e., ceiling) or minimum 
(i.e., floor) value detectable by microarrays. This phenomenon, known as the ceiling/floor effect, 
may result in such pairs of variants being spuriously identified as epistasis.125 Interactions caused 
by the ceiling/floor effect have a characteristic pattern of effects: the main effects of both 
variants have the same direction, and the interaction terms are in the opposite direction. For 
example, both main effects may increase gene expression, but the interactions will decrease gene 
expression. An example of an interaction putatively caused by the ceiling effect is shown in 
Figure 5. Of 1,119 locus pairs, 48 exhibited a pattern consistent with the ceiling/floor effect. It is 
possible that true genetic interactions could also produce this pattern; consequently, I consider 
this an upper bound of the influence of ceiling/floor artifacts within our analysis.  
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Figure 5. The interaction between rs1783165 and rs1673426 associated with the expression 
of PKHD1L1 may be a ceiling effect. The ceiling effect, caused by limitations in the detectable 
range of gene expression, has a hallmark pattern – both variants have main effects with 
concordant direction of effect, and the interaction term has a discordant direction. (A) The minor 
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allele of rs1673426 increases the expression of PKHD1L1. (B) The minor allele of rs1783165 
also increases the expression of PKHD1L1, meaning both variants have a concordant direction of 
effect. The interaction plot (C) depicts the mean gene expression for all individuals with the 
specified genotype combination, with each line representing the number of minor alleles at 
rs1673426.  When there is only one minor allele at rs1673426, the mean gene expression 
increases for each minor allele at rs1783165; however, when there are two minor alleles at 
rs1673426, the increase in gene expression due to minor alleles at rs1783165 reaches a 
‘maximum’ at one minor allele. There is no additional increase in expression for having two 
minor alleles at rs1783165. This is denoted by the flat line connecting the two genotype 
combinations. Given that each minor allele at rs1783165 increases gene expression on the 
background of one minor allele at rs1673426, and that the ‘maximum’ reached on the 
background of two minor alleles at rs1673426 is very close to the maximum gene expression 
levels possible to observe, I consider this an example of the ceiling effect. 
 
 
The interpretation of microarray data is also complicated by genetic variants in the probe 
binding site, as different alleles may have different affinities for the probe. Probes containing any 
HapMap variant had previously been removed from the analysis;53,117 however, HapMap does 
not provide comprehensive coverage of genetic variants. Consequently, I looked in a subset of 
individuals from the discovery analysis (n=174) with low-coverage sequencing data through the 
1KG Project to see if genetic variants within the probe binding site may result in apparent 
interactions.  The probes for 508 of 1,119 ieQTL contained a SNPs or indel in the 1KG Project. 
The probes for 255 ieQTL contained at least one common (MAF > 5%) variant. While the 
conditional analysis (Methods) performed later would likely account for the effect of these 
variants, I did not consider ieQTL with a common variant in the binding site evidence for 
biological epistasis.  The probes for the remaining 253 ieQTL contained at least one rare variant, 
but no common variation. To determine if these rare variants could result in the interaction, I 
performed the interaction analysis using only the 1KG individuals who did not have a rare 
variant in the probe binding site.  The interactions for 200 ieQTL remained nominally significant 
(p < 0.05) when all individuals with rare variants were removed.  Consequently, the interactions 
for 811 ieQTL are not attributable to variants within the probe binding sites. 
 
Missing genotype combinations may result in ieQTL 
 
Linear regression models for epistasis may be unable to accurately decompose variance between 
genetic terms if there is either LD between the interacting variants or if there are missing 
genotype combinations. The issue of LD has previously been explored, and the Cordell model is 
robust to LD between variants when all genotype combinations are present.89 Consequently, I 
examined all interactions within the discovery dataset to see if all of the nine possible two-locus 
genotype combinations were present. For 457 of the 1,119 ieQTL, at least one genotype 
combination was absent. While failure to see certain two-locus genotypes may be due to lethal 
combinations, and thus perhaps is evidence for epistasis, it may also simply be a result of certain 
combinations being uncommon due to allele frequencies and the proximity between variants. 
Either way, the statistical model used cannot provide robust estimates unless all genotype 
combinations are present, and therefore, I do not consider these interactions as evidence for 
biological epistasis. 
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Haplotype effects captured through complex LD patterns may produce ieQTL 
 
In some LD architectures, a combination of two variants can identify haplotypes. While there is 
evidence to suggest haplotypes form in response to biological interactions between variants,88,126 
haplotypes may simply carry a single variant that additively regulates gene expression. Thus, 
interactions between two variants in LD with one another may simply be tagging a cis-eQTL. 
Wood et al. demonstrated that this could occur even when strict LD-pruning thresholds (r2 > 0.1 
or D’ > 0.1) were used; therefore, I consider it unlikely that any LD-pruning threshold would be 
sufficient to eliminate confounding by cis-eQTL.83 Consequently, I adopted a two-stage strategy 
to address haplotype effects, wherein I first use a lenient LD-threshold to filter out interactions 
and then directly tested whether the interaction can be accounted for by cis-eQTL.  
 
In the first stage, I used LD-patterns to filter out variants in moderate LD with one 
another, as they likely represent a haplotype. I did this by first removing all interaction models 
composed of variants in modest LD with one another (r2 > 0.6) from all portions of the study, as 
previously mentioned. I then investigated whether or not variants within the same interaction 
model were in modest LD with one another as assessed by D’; of the 1,119 interacting loci, 806 
had D’ values < 0.6. I did not consider any of the variants with D’ thresholds exceeding this 
threshold as evidence for epistasis, as they likely carry a single variant driving the effect. An 
example of this phenomenon observed in our data is illustrated in Figure 6. The distribution of 
LD statistics, both r2 and D’, for interaction models is shown in Figure 3.  
 
 
 
Figure 6. Interactions impacting the expression of CPEB4 may represent haplotype 
effects.  (A) A significant interaction between rs6864691 and rs969518 regulating the expression 
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of CPEB4 was identified. The cis-eQTL rs72812817 mediated this interaction in the conditional 
analysis; however, none of these variants were within putative regulatory elements in GM12878 
assayed by the ENCODE Project. However, a D' heatmap (B) of the region (the numbers 
correspond to SNP labels in A) illustrated that an indel, rs144869372, always occurred on the 
background of the cis-eQTL (D' = 1). This occurs despite modest r2 values, as shown in the r2 
heatmap of the region (C). There is evidence from ENCODE (A) suggesting the indel may be 
functional, as it occurs within both a ChromHMM strong enhancer (yellow) and a CTCF binding 
peak in GM12878.  (D) Notably, the indel is predicted to alter the binding of CTCF by 
HaploReg, by altering the last three nucleotides in the binding motif.  Given the functional 
genomics evidence, the indel may be the causal variant and is detected by interactions that tag 
the haplotype carrying the indel. 
 
 
In the second stage of the analysis, I directly tested whether or not the interaction could 
be accounted for by cis-eQTL by conditioning the interaction on each of the target gene’s cis-
eQTL in turn. I first identified all nominal, common cis-eQTL (p < 0.05) for the interaction’s 
regulated gene using a subset of individuals from our discovery dataset (n=174) with sequencing 
data available through the 1KG Project so that I would have a comprehensive list of genetic 
variation. While the 1KG sequencing data is low coverage, it is extremely unlikely I would fail 
to detect the effect of a common cis-eQTL – 1KG estimates they had 99.3% power to detect 
variants of 1% frequency.118 Even if a common cis-eQTL was missed, all variants that could tag 
it through LD would additionally have to be absent for its effect to not be captured in the 
conditional analysis.  I then created all pairs of cis-eQTL and ieQTL for the same gene. For each 
of these combinations, I performed a conditional analysis in which the additive and dominant 
main effect for the cis-eQTL were incorporated into both the full and reduced model used in the 
LRT to determine the significance of the interaction.  The majority of interactions appeared to be 
mediated by cis-eQTL (Figure 7); however, 139 of the 965 testable ieQTL remained significant 
(p < 0.05) in all conditional analyses performed, indicating that these interactions are not 
explained by cis-eQTL.  
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Figure 7. The interacting SNPs regulating ACCS are likely tagging a single-variant cis-
eQTL through linkage disequilibrium. The interaction between rs178501 and rs7121151 is 
mediated by the cis-eQTL rs2074038 in the conditional analysis (interaction p-value > 0.05). (A) 
While the interacting variants are in low LD with the cis-eQTL based on r2, their high D’ 
indicates they often occur on the same haplotype. (B) The interacting variants are not located 
within DNase hypersensitivity sites, predicted chromatin states with a regulatory function 
(GM12878 Combined), or any of the uniform binding peaks identified for all transcription 
factors tested in GM12878 by ENCODE; however, the cis-eQTL is located within the canonical 
promoter for ACCS, a DNase hypersensitivity site, and numerous transcription factor binding 
peaks identified in GM12878 by ENCODE. (C) Notably, the cis-eQTL occurs within a binding 
peak for both ELF1 and SPI1 in GM12878, and also alters the binding motifs of these 
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transcription factors at the position highlighted in orange. Thus, the cis-eQTL rs2074038 is likely 
the causal variant, and the interaction is simply capturing its effect through LD. 
 
Population specific eQTLs may produce statistical interactions 
 
In our discovery and replication analyses I analyzed multiple ethnicities together. When there are 
population differences in both the distribution of genotypes and phenotypes, analyzing multiple 
populations together can lead to spurious results, due to a phenomenon known as population 
stratification. The population normalization procedure applied to the gene expression data 
removes systematic population differences in the phenotype, thereby enabling multiple 
ethnicities to be combined for analysis without risk of known complications from population 
stratification. While this approach has been used in other studies, I also controlled for the top 
three PCs in our analysis to adjust for residual ethnicity-dependent effects.117,127 Furthermore, I 
performed a stratified analysis, wherein I tested each of the 1,119 ieQTL in each of the three 
discovery ethnicities (CEU, YRI, and CHB+JPT) separately. While the Cordell model was not 
robust in the stratified analysis in many cases (due to the reduced sample size, all nine possible 
two-locus genotype combinations were often not observed in all populations), 859 of 1,119 
ieQTL were at least nominally significant (p < 0.05) in at least one population, suggesting that 
population stratification is unlikely to account for their significance.  
However, the interaction for 260 ieQTL was completely attenuated in the stratified 
analysis. In some cases, this may be attributed to reduced power to detect effects as the sample 
size is smaller; however, it could also suggest that interaction testing was subject to a novel form 
of population stratification. Upon further investigation, I found that 234 of 260 ieQTL attenuated 
in the stratified analysis involved at least one population-specific cis-eQTL, meaning that a 
variant was only a significant cis-eQTL in a subset of populations. Population-specific cis-eQTL 
may be a product of reduced power to detect effects when allele frequencies are different 
between populations; however, there were also instances in which variants with very similar 
allele frequencies had different marginal effects across populations (Figure 8).54 Such variants 
might be a product of population-dependent ability to tag causal cis-eQTL due to differential LD 
patterns. In relation to interaction testing, systematic differences in both the main effect of each 
variant and the frequency of two-locus genotype combinations between populations resulted in a 
spurious interaction signature; an example is provided in Figure 9. To investigate whether 
population-specific effects may impact the 859 ieQTL that were nominally significant in at least 
one population, I calculated the within-population LD between each pair of interacting variants. 
689 of 859 ieQTL were significant in at least one population where the variants were not in LD 
with one another (r2 and D’ < 0.6) (Supplemental Table 3, provided by Fish et al.124). I did not 
consider the 170 ieQTL that were exclusively significant in populations with population-specific 
haplotypes as clear evidence for biological epistasis. Ultimately, 689 of the 1,119 ieQTL were 
inconsistent with population-specific effects. 
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Figure 8. Investigation of population-specific cis-eQTL.   To investigate whether or not 
population-specific cis-eQTL were caused by reduced power to detect significant marginal 
effects in the stratified analysis, or by different marginal effects for the same variant, I performed 
pairwise comparisons of MAF, additive β (marginal), and p-value (of the cis-eQTL) by ethnicity. 
 
 
 
Figure 9. Population specific eQTLs may underlie ieQTL regulating C12orf54. The 
interaction between rs2731091 and rs4760707 regulating C12orf54 replicated, but was not 
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nominally significant (p < 0.05) in any population in the stratified analysis. (A) Due to the 
population normalization procedure, there are not systematic differences in the expression of 
C12orf54 between populations; however, I found that each variant was a population-specific cis-
eQTL. (B) rs4760707 was a cis-eQTL in CHB+JPT (p=7.25x10-6), but not in YRI (p=0.17) or 
CEU (p=0.96). (C) rs2731091 significantly regulated gene expression as a cis-eQTL in YRI (p = 
7.28x10-6), but not CEU (p = 0.14) or CHB+JPT (p=0.84).  (D) There were clear population 
differences in the frequency of two-locus genotypes between populations; in combination, it 
appears the population differences in two-locus genotypes and population specific cis-eQTL 
produced a nuanced form of population stratification.  
 
IeQTL can be entirely accounted for by alternative mechanisms 
 
Ultimately, I investigated whether confounding factors could cumulatively account for all the 
interactions identified in this analysis (Supplemental Table 3124; Table 3). Of the 1,119 
interacting genomic loci identified, 90 significantly replicated using a Bonferroni multiple testing 
correction threshold. Of these, 26 ieQTL could be explained by technical artifacts (i.e., the 
ceiling/floor effect and/or variants within the probe binding sites). 50 of the remaining 64 ieQTL 
could be explained by statistical artifacts (i.e., population stratification and/or missing 
genotypes). Biological explanations other than epistasis – namely haplotype effects or the 
tagging of cis-eQTL – could account for all remaining ieQTL that replicated at the most stringent 
Bonferroni level.  
 
 
Confounder All Interactions (n=1,119) Bonferroni Replicating  
Interactions (n=90) 
Total (%) Total (%) 
Ceiling/Floor 
Effect 
48 (4.30) 11 (12.22) 
Variants in Probe 308 (27.52) 15 (16.68) 
Cis-eQTL 980 (87.58) 78 (86.68) 
D’ Haplotype 313 (27.97) 43 (47.78) 
Population-
Specific Effects 
430 (38.43) 58 (64.44) 
Missing 
Genotypes 
457 (40.84) 37 (41.11) 
 
Table 3. Proportion of Interactions Consistent with Confounding Factors. I counted the 
number of interactions consistent with each alternative explanation; interactions can be 
consistent with multiple confounders. I considered two categories of interactions: all interactions 
identified (n=1,119), and the subset of those that replicated with p-values exceeding the 
Bonferroni multiple testing correction threshold for the entire replication analysis (n=90).  
 
 
We additionally investigated the impact of filtering out interactions consistent with 
confounding prior to the replication analysis. Removing these interactions prior to replication 
testing had a considerable influence on the multiple testing correction threshold: only 86 of the 
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1,119 interactions identified in the discovery analysis were not consistent with the ceiling/floor 
effect, population stratification, variants within the probe binding site, missing genotype 
combinations, haplotype effects, or the tagging of cis-eQTL (Supplemental Table 4, provided in 
Fish et al.124). 37 of the 86 ieQTL had sufficient data to be tested in the replication analysis, and 
while none replicated at the adjusted Bonferroni multiple testing correction threshold, two 
interactions did replicate with nominal significance (p < 0.05). One of these, the interaction 
between rs1549791 and rs7115749 to regulate APIP, did not have a consistent direction of effect 
between the discovery and replication datasets (Figure 10), and thus was not considered evidence 
for epistasis. The remaining interaction, between rs1262808 and rs11615099 regulating the 
expression of MYRFL, had concordant effects in both the discovery and replication datasets 
(Figure 11). As it did not pass the multiple testing correction threshold in the initial replication 
analysis (p=2.03x10-3) though, I further examined it additional datasets.  
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Figure 10. The interaction between rs1549791 and rs7115749 associated with the expression 
of APIP is not consistent between the discovery and replication datasets.   In the interaction 
plot, each individual is categorized according to their two-locus genotype at rs1549791 and 
rs7115749. This results in nine possible genotype combinations, and the mean expression of 
APIP for each combination is shown here for the (A) discovery and (B) replication datasets. 
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There are markedly different patterns in gene expression by two-locus genotype between the two 
datasets, illustrating the putative interaction does not replicate with a consistent direction of 
effect. 
 
 
 
Figure 11. Despite consistent replication, the interaction regulating MYRFL is attributable 
to cis-eQTL.  In each interaction plot, all individuals are categorized according to their two-
locus genotype at rs1262808 and rs11615099.  The mean expression of MYRFL for all 
individuals with each of the nine possible two-locus genotypes is shown here for the (A) 
discovery; (B) replication; (C) Mayo, cerebellum; (D) Mayo, cortex; (E) GTEx, whole blood 
datasets.  The interaction plot illustrates a consistent trend across all datasets, this interaction is 
mediated by cis-eQTL. (F) Conditional cis-eQTL analyses were conducted in the discovery 
(CEU only, yellow); GTEx (purple); Mayo, cerebellum (teal); and Mayo, temporal cortex 
(orange). For each conditional analysis, the conditional LRT p-value is plotted by the genomic 
position of the cis-eQTL conditioned on. The p-value peak observed in this region illustrates that 
cis-eQTL completely attenuate the interaction when they are conditioned on. 
 
Discussion 
 
In this study, I analyzed more than 21 million pairs of cis-regulatory variants for epistatic 
interactions influencing gene expression, and found limited evidence for epistasis within the cis-
regulatory region of genes. Fewer than 2% of genes tested (165 of 11,465) had significant 
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interactions between regulatory genetic variants that appeared to influence their expression in the 
tightly controlled context of LCLs. Nonetheless, 90 of the 1,119 significant interactions 
replicated in independent datasets. I then performed a comprehensive investigation of known and 
novel potential confounding factors on the identified interactions (haplotype effects, ceiling/floor 
effect, single variant eQTL tagged through LD, missing genotype combinations, population 
stratification, and others), and found that all the interactions – even those that replicated – could 
be explained by at least one technical, statistical, or biological confounder. Thus, our findings do 
not support a major role for large effect interactions between common variants within the cis-
regulatory region influencing the regulation of gene expression in LCLs. 
Additionally, this study provides a trait-independent framework for protecting future 
interaction studies from confounding. Prior to performing any association testing, there are two 
levels of quality control required for statistical studies of epistasis: those adopted in GWAS best 
practices128–131, which are aimed at ensuring individual genetic variants are called with high 
accuracy, and then those that check whether a given pair of genetic variants is appropriate for 
interaction testing (i.e. missing genotype and the within-pair LD filters). Even when these quality 
control measures are applied prior to the discovery analysis, significant interactions need to be 
further examined for evidence of confounding by single variants tagged through LD and for 
population-specific effects. I advise removing interactions consistent with these confounders 
prior to replication, as this reduced the number of putative interactions carried forward 
substantially, and consequently, the multiple testing penalty. The ceiling/floor effect is a more 
complicated confounder, as it is difficult to statistically disambiguate whether consistent 
interactions are caused by technical limitations or by biological epistasis. Consequently, I 
recommend interactions consistent with the ceiling/floor effect be flagged, rather than filtered 
out, and validated with an alternative technology if possible. It is still critical to replicate 
interactions to ensure they have robust, consistent effects, despite replication being insufficient to 
protect against confounding. Given how pervasive confounding factors are, it is critical to 
explicitly account for them through additional quality control procedures and post-hoc analyses 
in future studies to reduce spurious results.  
To strike a balance between maximizing the power to detect effects and thoroughly 
investigating potentially interacting loci, I performed a focused analysis of common variants 
with significant marginal effects in the cis-regulatory region, which harbors the majority of 
known regulatory elements. I was moderately powered to detect interactions between common 
variants in low LD with one another with effects commensurate with the single-locus eQTL 
found in this dataset. While additional statistical interactions with either smaller effect sizes or 
between less frequent genotype combinations would likely be identified with increased power, 
every example of a significant interaction I did identify was consistent with at least one 
confounding factor. Thus, I did not find compelling evidence that cis-regulatory interactions 
contribute strongly to the genetic architecture of gene expression; however, there are several 
additional limitations to our study. First, cell lines are a model system, and thus are not perfectly 
representative of primary tissue. Second, I analyzed multiple ethnicities simultaneously in an 
effort to increase sample size; however, doing so also increased the heterogeneity of our sample, 
which may have obfuscated some interactions. Therefore, our findings do not preclude the 
existence of epistasis within the cis-regulatory region, and I recommend that future studies of 
regulatory epistasis consider potential interactions that: 1) occur within haplotypes (consistent 
with reports from Corradin et al.126 and Lappalainen et al.88), 2) have smaller effect sizes than 
those detected in similarly powered single-locus eQTL studies, 3) occur among less frequent 
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genotype combinations, including rare variants 4) involve variants without marginal eQTL 
effects (though evidence in model organisms suggests these are rare1), and/or 5) are context-
dependent (e.g. inducible eQTL effects). Observing statistical interactions in these contexts could 
reconcile our findings with molecular studies, many of which use mutagenesis to generate 
genetic variation that would not be observed in population-based studies, that illustrate that 
transcription factors (TF) interact with each other to influence promoter and enhancer 
activity.77,78,132  
Genetic interactions involving distant variants could also be a mechanism through which 
epistasis influences complex traits. However, I did not investigate interactions involving variants 
outside of the cis-regulatory region because evidence from eQTL studies in humans suggests that 
trans-eQTL effects are less robust, less common, and have smaller effect sizes.133,134  This, 
coupled with the substantial increases in the number of association tests required to investigate 
trans- interactions, would have resulted in reduced power to detect such effects. Nonetheless, 
interactions between distant variants (i.e., gene by gene interactions) may still be important to the 
biology of disease in humans. Increases in the sample size of eQTL datasets and the 
corresponding increases in statistical power will enable future in-depth studies of trans-
interactions that may help to illuminate the biological mechanisms through which genetic 
variants are associated with disease. However, trans- interactions are not protected from many of 
the confounders influencing the study of cis- interactions,83 and thus studies of trans- interactions 
will need to explicitly account for these issues as well.  
Our findings (along with prior reports)83 illustrate that significant interaction effects can 
be due to a variety of confounding factors. This demonstrates that significant statistical 
interactions do not necessarily imply either a biological relationship with the phenotype, or 
between the variants themselves.  To account for this, some confounders can be addressed as part 
of quality control procedures prior to performing any association tests (i.e., missing genotype 
check, removing variants in probe binding sites, and LD-filtering), while others – such as 
confounding by single variants with strong effects – will likely require specific post-hoc analyses 
after the initial association is identified. Furthermore, replication – long held as the gold standard 
for genetic association studies – does not safeguard against these confounders, as they can be due 
to artifacts that are consistent across multiple datasets. Given the pervasive nature of 
confounding, it must be considered in all future studies of epistasis. The analytic approach used 
in this study provides a trait-independent framework for explicitly examining confounding 
factors in interaction studies and avoiding reporting spurious results. 
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CHAPTER 3 
EPISTASIS IN ADMIXED POPULATIONS 
 
 
Introduction 
 
Regulatory epistasis may occur between variants on the same haplotype, which are combinations 
of physically linked genetic variants that co-occur more often than anticipated. As reviewed in 
detail in Chapter 1, evidence from reporter assays clearly demonstrating epistasis between 
variants typically investigate a narrow genomic region, unlikely to be broken apart by 
recombination in natural populations.78 Additionally, follow-up of GWAS-Catalog variants has 
demonstrated that multiple variants on the associated haplotype influence the expression of the 
same target gene in the rare instances when those variants are separated via recombination.87 
Finally, genetic variants that are associated with decreased gene expression levels are associated 
with an increased burden of recently-derived rare variants.88,135  However, the study of epistasis 
within haplotypes is complicated by the same properties that make it biologically intriguing; the 
tight linkage between genetic variants on the same haplotype inherently means that all 
combinations of variants are either rarely observed, or absent. Consequently, linear regression 
models are unable to accurately partition phenotypic variance to genetic components, thereby 
complicating the study of epistasis within haplotypes.89   
 The structure of haplotypes is in large part dictated by the location of recombination 
hotspots.  Indeed, the genome can be divided into blocks of variants in high LD with one 
another, separated by regions that frequently undergo recombination events.136–138  These 
boundaries are highly correlated between ethnicities; however, there are some 
discrepancies.136,139  First, LD-blocks are typically shorter in African-descent populations; this is 
consistent with the Out-of-Africa hypothesis, as both population bottlenecks increase the length 
of LD-blocks in European and Asian-descent populations, and older populations (i.e., African) 
have had more recombination events that reduce the length of LD-blocks.139,140 Second, 
recombination rates also vary considerably by population. The location of recombination 
hotspots is regulated by PRDM9, a  methyltransferase with a zinc finger domain that recognizes 
specific sequence motifs.141–143 In European descent populations, there are two common alleles 
of PRDM9, A and B, which occur with a frequency of 90% and 5% respectively.141 Individuals 
with rarer alleles that no longer recognize the canonical binding motif have drastically shifted 
landscapes of recombination hotspots.141  In African descent populations, there is third allele, C, 
which occurs with a frequency of ~35%.144,145 Individuals carrying the C allele of PRDM9 do not 
appear to share any of the recombination hotspots recognized by the A allele, and vice versa.144 
This has resulted in drastically different recombination landscapes between European and 
African descent populations; there are more than two thousand recombination hotspots that are 
observed in populations of West African descent, but are absent in European descent 
populations.91  Thus, there are population-level differences in haplotype structure that could 
potentially be exploited to investigate epistasis within haplotypes. 
 Due to population-level differences in recombination hotspots, admixed populations 
provide a unique opportunity to investigate epistasis within haplotypes.  I hypothesize that 
African-specific recombination hotspots may disrupt European haplotypes, and vice versa.  
When ancestral haplotypes are broken apart by these recombination events, there is an increased 
likelihood of observing all possible genotype combinations, such that epistasis within the 
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ancestral haplotype can be investigated using traditional linear regression approaches discussed 
in Chapter 2.  
In this Chapter, I investigate this hypothesis in African Americans.  African Americans 
are a population derived from a two-way admixture event between European-descent and 
African-descent individuals. Historical records indicate this admixture event began with the 
Trans-Atlantic slave trade, in which approximately 11 million individuals were forcibly brought 
form coastal regions of Africa to the Americas throughout the 15th to 19th centuries.146,147 Current 
estimates predict that, on average, six to seven generations have passed since the initial 
admixture event.148,149  On average, African Americans have approximately 20% ancestry from 
European descent populations with the remainder of African descent, although these proportions 
can vary substantially between individuals.148–150  Various methods exist that predict local 
ancestry at specific genomic loci by comparing the observed, inferred haplotypes to those seen in 
reference populations of African and European descent.92,93,95 
In this Chapter, I leverage transitions in local ancestry between European and African 
descent to identify genomic regions in which ancestral haplotypes might be disrupted.  I 
investigated this in 9,559 African American adults with EHR linked to genetic data collected on 
the Metabochip, a custom genotyping array.97,151,152 The Metabochip is designed to fine-map 
approximately two hundred genomic loci previously associated to with type 2 diabetes, obesity, 
and coronary artery disease, and corresponding endophenotypes. The wealth of phenotypic data 
within the EHR allowed me to explore whether these transitions in local ancestry interacted with 
nearby genetic variants to influence three categories of phenotypes: those the Metabochip was 
designed around; phenotypes with associations in the GWAS-Catalog in Metabochip regions; 
and finally, all possible phenotypes (i.e., a PheWAS).  Thus, I was able to investigate a wide 
array of possible phenotypic consequences resulting from the disruption of ancestral haplotypes 
within Metabochip regions. 
 
Subjects and methods 
 
Subjects and genotyping 
 
In this Chapter, I investigated whether local ancestry transitions interacted with genetic variants 
to influence a variety of EHR-derived phenotypes in 9,559 African-American adults.  All 
samples used in this analysis were part of the Epidemiologic Architecture for Genes Linked to 
Environment (EAGLE) study, which used Vanderbilt University’s de-identified biorepository to 
link patient EHR data with their genetic data.152  EAGLE selected individuals for inclusion based 
upon minority-status, rather than for specific health phenotypes. Consequently, this is a cross-
sectional study design that minimizes ascertainment bias.  This sample was comprised of 6,249 
females, and 3,310 males. The mean age was 46.9 years, with a standard deviation of 16.4 years. 
The mean BMI was 28.9, with a standard deviation of 6.56.  All individuals self-reported as 
African American. We inferred global ancestry from our local ancestry estimates, by determining 
the proportion of variants with European ancestry.  In this sample, we observed a mean European 
ancestry of 21.5%, with a standard deviation of 14.5%, consistent with the average proportion of 
European ancestry reported within the literature. 
The samples were genotyped on Illumina’s Metabochip, a custom array of almost 
200,000 SNPs that targets genomic regions previously associated with type 2 diabetes, obesity, 
and coronary artery disease for fine-mapping purposes.151  As part of quality control, variants 
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were removed that did not have at least a 95% genotyping efficiency rate, or that did not vary in 
this dataset, leaving a total of 192,093 variants for analysis.   
 
Determining local ancestry 
 
Determining local ancestry is a two-step process: first, individual chromosomes are phased, and 
then the local ancestry is assigned. I phased the data using the program SHAPEITv296 and the 
1000 Genomes Phase 3 reference panel (available for download at 
https://mathgen.stats.ox.ac.uk/impute/impute_v2.html#reference).  171,439 variants were 
successfully phased; when variants failed it was typically due to inconsistencies with the 
reference panel.  I then used RFMixv1.5.4 to determine the local ancestry of the phased genetic 
data, using a window size of 0.1 cM, and a minimum node size of 5.  For the phasing reference 
panel, I used all YRI and CEU individuals from 1000G, phase 3v5a.  I developed a custom 
pipeline to perform all necessary data processing and file-type conversions between these 
programs, which will be made publicly available.  
 
Phenotype processing and quality control 
 
Typically, individuals have multiple measures for body mass index (BMI), systolic blood 
pressure (SBP), diastolic blood pressure (DBP), and low-density lipoprotein (LDL) levels. To 
assign a single score to each individual, I took distinct approaches depending on the phenotype.  
For BMI, I computed the median measurement for each year with data available in the EHR, and 
then computed the median of these scores.  For SBP and DBP, I had three distinct scores: the 
first measurement, regardless of medication status; a pre-medication measurement, which was 
the median of yearly medians for measurements made prior to any references to blood pressure 
medications; and a post-medication measurement, which was the median of yearly medians for 
measurements made after a reference to blood pressure medications.  Similarly for LDL, three 
distinct measurements were used for analysis: the median of yearly medians, regardless of 
medication status; a pre-medication measurement, which was the median of yearly medians for 
measurements made prior to any references to lipid medications; and a post-medication 
measurement, which was the median of yearly medians for measurements made after a reference 
to lipid medications.  For all of the above phenotypes, I then performed the following quality 
controls: I removed clearly non-valid scores (i.e., scores of zero or one), and then removed 
outliers (those scores more than three standard deviations away from the mean).  The 
distributions of each phenotype are provided in Figure 12. 
 
Statistical modeling 
 
Given that local ancestry is specific to a given chromosome, I performed all analyses on the level 
of the chromosome, rather than the individual.  I used linear regression to determine whether 
local ancestry transitions interacted with the allele to influence the phenotypes of interest, using 
the model: 
𝑦 = 𝐴 + 𝐿𝐴 + 𝑇𝑅𝐴𝑁𝑆 + 𝐴 ∗ 𝑇𝑅𝐴𝑁𝑆 + 𝑃𝐶1−3 + 𝐴𝐺𝐸 + 𝐺𝐸𝑁𝐷𝐸𝑅 + 𝐵𝑀𝐼 
where y is the phenotype of interest; A corresponds to the allele status (binary variable: 0, 
absence of the allele; 1, presence of the allele); LA corresponds to the local ancestry at the 
variant (binary variable: 0, African ancestry; 1, European ancestry); TRANS indicates the 
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presence of a local ancestry transition within the Metabochip region (binary variable: 0, no 
transition; 1, no transition); A*TRANS represents the interaction term between the allele and 
local ancestry transition (binary variable: 1 indicates presence of both the allele and a local 
ancestry transition; 0 encompasses all other possibilities).  The covariates included varied by the 
analysis. AGE, GENDER, BMI, and the top three principal components (PC1-3) were included in 
the investigation of phenotypes the Metabochip was designed to fine-map (BMI was not a 
covariate when it was the phenotype being investigated). AGE, GENDER, and the top three 
principal components (PC1-3) were included in the investigation of phenotypes derived from the 
GWAS-catalog with associations in Metabochip regions.  No covariates were included in the 
PheWAS. In the case of binary phenotypes, logistic regression was used. 
 
Results 
 
In this Chapter, I investigate whether transitions in local ancestry interacted with genetic variants 
to influence three distinct categories of EHR-derived phenotypes in an admixed population. All 
of these analyses require local ancestry, and the identification of genomic regions harboring 
transitions in local ancestry. To derive local ancestry, I first phased the genetic data using 
SHAPEIT296, then assigned local ancestry using RFMix92.  I was able to pinpoint the location of 
local ancestry transitions, e.g. where changes in continental ancestry occurred along the 
chromosome, using the local ancestry calls.  For each phenotype, I then analyzed the significance 
of single variants, regardless of local ancestry, to determine if there was genetic association 
within a region.  Then, I performed an interaction analysis to determine if local ancestry 
transitions interacted with variants to influence the phenotype.  I examine three separate 
categories of phenotypes: those that the Metabochip was designed to fine-map; those with 
associations in Metabochip regions in the GWAS Catalog for African-descent populations; and 
finally, all phenotypes encoded by ICD-9 with sufficient numbers of cases and controls.  The 
first two categories are targeted analyses based on previous associations, whereas the final 
category – a PheWAS – is designed to discover novel associations. A table of the analyses 
performed is provided as a guide in Figure 12. 
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Figure 12. Outline of the analyses performed to investigate interactions between local 
ancestry and variants.  In this Chapter, I investigated three categories of phenotypes: previous 
associations to phenotypes Metabochip was designed to fine-map; previous associations in 
African-descent populations in the GWAS Catalog; and all ICD-9 phenotypes contained in the 
EHR. For the first two phenotype categories, I first conducted analyses to investigate whether 
prior associates generalized to our sample. In contrast, investigation of all the ICD-9 phenotypes, 
which were translated to phecodes, was designed to identify novel associations.  I then conducted 
a second set of analyses for each of these phenotypes to investigate whether variants interacted 
with local ancestry transitions to influence the specified phenotypes.  
 
 
European associations for phenotypes targeted by Metabochip do not generalize to African 
American populations  
 
The Metabochip genotyping array was designed to fine-map genetic associations for type 2 
diabetes, coronary artery disease, myocardial infarction, and their associated quantitative traits in 
genome-wide association studies.151 Based on prior associations, each of the over 200 densely-
genotyped genomic regions is assigned to specific phenotypes. I analyzed quantitative traits 
associated with these diseases that are frequently collected as part of routine clinical visits, 
including: body mass index (BMI), systolic blood pressure (SBP), diastolic blood pressure 
(DBP), and low-density lipoprotein (LDL) levels (Chapter 3; Subjects and methods: Phenotype 
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processing and quality control).  Given the prevalence of drugs designed to alter both blood 
pressure and lipid levels, I investigated both a baseline, pre-, and post-medication value for SBP, 
DBP, and LDL levels (Methods).  The distribution for these traits resembles non-clinical 
populations, and there is a median of 5446 individuals with data for these phenotypes (Figure 
13).  
 
 
 
 
 
 
Figure 13. Distributions of EHR-derived SBP, DBP, LDL, and BMI measurements.  For 
each of the 9,559 African American individuals genotyped on the Metabochip as part of the 
EAGLE Project, I derived their SBP, DBP, LDL, and BMI values from their medical record 
(Methods). For SBP, DBP, and LDL there are three values – the first measurement in the 
medical record, the median of yearly medians prior to mention of phenotype-altering 
medications, and the median of yearly medians after the mention of phenotype-altering 
medications.  
 
To determine whether European-associations generalized to African Americans, I first 
performed a Metabochip-wide association test (Metabochip-WAS) for each of these traits. For 
each variant (MAF > 1%), I performed a linear regression analysis in which I assumed an 
additive genetic effect and included age, gender, the top three principal components (PCs), and 
BMI (except for when BMI was the trait of interest) as covariates. To adjust for multiple testing, 
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a trait-specific Bonferroni significance threshold was set. No variants for any trait passed this 
significance threshold (Figures 14-16), suggesting that either European associations do not 
generalize to African Americans, or that there was insufficient power to detect them in this 
dataset. 
 
 
 
Figure 14.  No variants significantly associated with SBP, DBP, LDL, or BMI in a 
Metabochip-WAS.  Manhattan plots for a Metabochip-WAS of A) SBP, B) DBP, C) LDL, and 
D) BMI are provided. The Metabochip-WAS Bonferroni multiple testing correction for each trait 
separately is 3.2x10-7, which none of the variants passed. 
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Figure 15. No variants significantly associated with pre-medication measurements for SBP, 
DBP, or LDL in a Metabochip-WAS. Manhattan plots for a Metabochip-WAS of pre-
medication measurements for A) SBP, B) DBP, and C) LDL are provided. The Metabochip-
WAS Bonferroni multiple testing correction for each trait separately is 3.2x10-7, which none of 
the variants passed. 
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Figure 16. No variants significantly associated with post-medication measurements for 
SBP, DBP, or LDL in a Metabochip-WAS. Manhattan plots for a Metabochip-WAS of post-
medication measurements for A) SBP, B) DBP, and C) LDL are provided. The Metabochip-
WAS Bonferroni multiple testing correction for each trait separately is 3.2x10-7, which none of 
the variants passed. 
 
Relative to many GWAS, our study has reduced power to detect effects given the smaller 
sample size. To improve power, I next performed a targeted association analysis wherein I only 
tested variants for association with each for these traits if they occurred in a Metabochip region 
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that had previously been associated with that trait (Table 4). Exclusively examining these regions 
dropped the number of association tests performed for each trait from a median of 156,004 to 
8,477; however, no variants passed a trait-specific multiple testing correction threshold in the 
targeted analysis, despite its greater leniency (Figure 17-19).  There were several suggestive 
associations though, which I hypothesized might be influenced by local ancestry transitions. To 
investigate this, I further filtered the Metabochip regions included in the targeted analysis: only 
previously associated regions with at least a hundred local ancestry transitions observed were 
considered.  Two regions apiece met these criteria for DBP, LDL, and BMI – none did for SBP.  
Notably, these regions were those with the significant variants from the broader targeted analysis 
for both BMI and LDL (Figure 17).  For common variants (MAF > 5%; LD-pruned at r2 > 0.9) in 
these regions, I then performed a regression analysis to determine if the presence of a local 
ancestry transition within the region interacted with the variant to influence the previously 
associated phenotype (Methods).  The significance of these interaction terms is provided in Table 
5; however, no terms passed either a Bonferroni multiple-testing correction threshold, or a false-
discovery rate (FDR) of 5%. Thus, there is little evidence local ancestry transitions interact with 
genetic variants to influence these phenotypes; however, there is also little evidence that there 
were any genetic associations within these regions. 
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Trait Regions Trait Regions 
LDL chr1:25525907-25908241  
chr1:55498949-55513521  
chr1:109655637-110043693 
chr2:21226560-21451827 
chr2:44057030-44100849 
chr5:74568112-74956052 
chr5:156331094-156505233 
chr6:16104254-16134837 
chr6:160468278-160579527 
chr7:44374092-44676286 
chr8:126441650-126543928 
chr9:136042324-136482476 
chr11:126219429-126279347 
chr12:121304826-121488876 
chr16:71996291-72147683 
chr19:11183837-11211208 
chr19:19301232-19792250 
chr19:45396899-45444266 
chr20:39083142-39128578 
chr20:39613984-40010045 
BMI chr1:72513687-72958905 
chr1:74961817-75078975 
chr1:177753776-177936525 
chr2:471136-719889 
chr3:85651797-86050826 
chr3:185747042-185862593 
chr4:45099376-45187658 
chr5:74562373-75123052 
chr6:50534485-51100751 
chr9:28403443-28499099 
chr11:8394189-8707147 
chr11:27452706-27749725 
chr11:47243424-48094879 
chr12:50168189-50290056 
chr14:30436558-30543794 
chr15:67649978-68215300 
chr16:19704224-20019432 
chr16:28306987-29001460 
chr16:53539509-54185787 
chr18:57727147-58094636 
chr19:34295278-34333501 
 
SBP chr1:11794676-11968356  
chr3:169087965-169195349  
chr4:81155937-81207963  
chr5:32689850-32867260  
chr5:157713315-157952955  
chr10:95869815-95949432  
chr10:104217441-104999266  
chr11:9886230-10370634  
chr11:16844924-16988268  
chr11:100497893-100698228  
chr12:89788633-90118890  
chr12:111681897-112225304  
chr15:74864568-75374591  
chr15:91390400-91441094  
chr17:43147554-43273187  
chr20:57660009-57790618 
DBP chr1:11824260-11909736  
chr3:169087965-169195349  
chr4:81155937-81207963  
chr4:103121726-103218446  
chr5:157713315-157952955  
chr6:25235303-26141375  
chr10:63381832-63553849  
chr10:104217441-104999266  
chr12:89824040-90118890  
chr12:111505708-113105952  
chr12:115343492-115438209  
chr15:74864568-75449674  
chr20:10941849-10998754  
chr20:57660009-57790618 
 
Table 4. Metabochip regions associated with LDL, BMI, SBP, and DBP.  This chart indicates 
which Metabochip regions were previously associated with each trait, and therefore included in 
the targeted analysis. 
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Figure 17.  No variants significantly associated with SBP, DBP, LDL, or BMI in a targeted 
analysis of previously associated regions.  Manhattan plots for a Metabochip-WAS of A) 
baseline SBP, B) baseline DBP, C) baseline LDL, and D) BMI are provided.  The Bonferroni 
multiple-testing correction threshold for each trait in the targeted analysis (SBP: p = 6.57x10-6, 
DBP: p = 5.35x10-6, LDL: p = 7.23x10-6, BMI: p = 3.83x10-6), which none of the variants 
passed, is indicated by the red line. Regions with at least 100 local ancestry transitions are 
highlighted in orange. 
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Figure 18. No variants significantly associated with pre-medication measurements for SBP, 
DBP, or LDL in a targeted analysis of previously associated regions. Manhattan plots for a 
Metabochip-WAS of pre-medication measurements for A) SBP, B) DBP, and C) LDL are 
provided. The Bonferroni multiple-testing correction threshold for each trait in the targeted 
analysis (SBP: p = 6.58x10-6, DBP: p = 5.35x10-6, LDL: p = 7.25x10-6), which none of the 
variants passed, is indicated by the red line. 
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Figure 19. No variants significantly associated with post-medication measurements for 
SBP, DBP, or LDL in a targeted analysis of previously associated regions. Manhattan plots 
for a Metabochip-WAS of post-medication measurements for A) SBP, B) DBP, and C) LDL are 
provided. The Bonferroni multiple-testing correction threshold for each trait in the targeted 
analysis (SBP: p = 6.58x10-6, DBP: p = 5.35x10-6, LDL: p = 7.21x10-6), which none of the 
variants passed, is indicated by the red line. 
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Trait 
 
Metabochip Region 
 
SNPs (N) 
Nominal 
(p < 0.05) 
 
Bonferron
i 
 
FDR = 5% 
BMI chr16:53539509-54185787 499 14 0 0 
 chr18:57727147-58094636 277 1 0 0 
DBP chr6:25235303-26141375 674 25 0 0 
 chr12:111505708-113105952 577 1 0 0 
LDL chr1:109655637-110043693 224 2 0 0 
 chr9:136042324-136482476 301 25 0 0 
 
Table 5. Local ancestry transitions do not significantly interact with variants to influence 
DBP, LDL, or BMI.  I tested whether local ancestry transitions interact with variants in 
previously-associated regions with at least 100 local ancestry transitions to influence the 
indicated phenotype (Methods).  Here, I report the number of SNPs tested within that region, and 
the number of interaction terms that passed various significance threshold cut-offs. No 
interactions were significant with multiple-testing corrections.   
 
There are two potential explanations for the lack of genetic association within these 
regions: there is insufficient power to detect these effects, or that European-associations do not 
generalize to African American populations. To distinguish between these two possibilities, I 
performed power calculations across a range of allele frequencies and effect sizes.  For each trait, 
I determined the minimum effect size that I had a power of 80% to detect using the actual sample 
size, mean, standard deviation, and number of association tests performed using Quanto.153  I 
considered both a rare (MAF = 5%) and a common (MAF = 25%) allele frequency to capture the 
range in power across the allele frequency spectrum.  Table 6 contains the effect sizes that I was 
well-powered to detect for each trait. In the GWAS Catalog, there are common variants reported 
for all four traits that have effect sizes greater than those I am well-powered to detect; these are 
additionally reported in Table 6. Thus, I was well-powered to detect effects commensurate with 
those observed in European-populations across a broad range of allele-frequencies, which 
suggests that European-associations did not generalize to this dataset. Consequently, the lack of 
genetic association within the region likely accounts for why no significant interactions between 
variants and local ancestry transitions were observed. 
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Trait 
Effect size 
detectable at 
MAF: 0.05 
Effect size 
detectable at 
MAF: 0.25 
GWAS Catalog 
Effect Size  
MAF ≥ 0.05 
SBP: First 3.75 mmHg 2.00 mmHg 5.43 mmHg 
SBP: Pre 3.75 mmHg 1.75 mmHg 5.43 mmHg 
SBP: Post 3.75 mmHg 2.00 mmHg 5.43 mmHg 
DBP: First 2.50 mmHg 1.25 mmHg 3.20 mmHg 
DBP: Pre 2.25 mmHg 1.25 mmHg 3.20 mmHg 
DBP: Post 2.50 mmHg 1.25 mmHg 3.20 mmHg 
LDL: First 8.25 mg/dL 4.25 mg/dL 12.30 mg/dL 
LDL: Pre 10 mg/dL 5.00 mg/dL 12.30 mg/dL 
LDL: Post 13 mg/dL 6.75 mg/dL 12.30 mg/dL 
BMI 1.25 units 0.75 units 1.54 units 
 
Table 6.  Targeted analysis is well-powered to detect anticipated effects for SBP, DBP, 
LDL, and BMI.  I calculated the effect size at which there was 80% power to detect effects for 
each trait, using the actual mean, standard deviation, sample size, and number of association tests 
performed. I considered both a rare allele frequency (MAF = 0.05) and a common allele 
frequency (MAF = 0.25). For each trait, I identified the strongest-effect variant associated in the 
GWAS Catalog for a common variant (MAF ≥ 0.05). 
 
Local ancestry transitions interact with variants to influence GWAS Catalog traits 
 
The GWAS Catalog32 contained additional phenotypes that had been associated to regions fine-
mapped by Metabochip.  I exclusively analyzed associations for variants that occurred in 
Metabochip regions with at least 100 observed local ancestry transitions, as I ultimately wished 
to investigate the interaction of these transitions with variants. I additionally limited the 
associations to those that made reference to African ancestry in the study sample, were for 
phenotypes that could be readily derived from the EHR, and had at least 200 cases in the EHR.  
This resulted in 28 phenotype-Metabochip region pairs (Table 7). I did not restrict the analysis to 
the specific variant referenced in the GWAS Catalog, due to both differential LD structure 
between populations and representation of different variants on different genotyping platforms. 
Instead, I tested all variants in the Metabochip region for association with the phenotype.  There 
was at least one nominal genetic association for each trait-Metabochip region pair, illustrating 
some level of genetic association within the region.  
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GWAS Catalog 
Trait 
Corresponding EHR Trait Metabochip Region 
Urate levels UricA* chr6:25235303-26141375 
Type 2 diabetes PAGE T2D Algorithm154 chr11:2444094-2943115 
Red blood cell 
traits 
RBC*; RDW* chr6:25235303-26141375 
Iron status 
biomarkers 
TIBC* chr6:25235303-26141375 
Weight Weight** chr16:53539509-54185787 
chr18:57727147-58094636 
Hematology traits Alb*; AlkP*; AN-GAP*; BUN*; Ca*; 
Cl*; CO2*; Creat*; GluBed*; Gluc*; 
Hgb*; K*; MCHC*; MCH*; MCV*; 
NA*; RBC*; RDW*; SGOT*; 
SGPT*; TBil*; WBC; MPV*; Plt-Ct*; 
TIBC* 
chr6:25235303-26141375 
Mean platelet 
volume 
MPV* chr12:111290599-113206306 
chr12:111505708-113105952 
chr12:111681897-112225304 
chr6:25235303-26141375 
Height Height** chr7:27784039-28282062 
Obesity-related 
traits 
BMI** chr16:53539509-54185787 
Platelet count Plt-Ct* chr12:111290599-113206306 
Coronary artery 
disease 
Cases at least one ICD-9 Codes (410 – 
414); all others were controls 
chr12:111290599-113206306 
chr12:111505708-113105952 
chr12:111681897-112225304 
chr13:110795080-111049623 
chr18:57727147-58094636 
LDL cholesterol First LDL-C measurement chr1:109655637-110043693 
chr1:109789347-109826136 
Body mass index BMI** chr12:111290599-113206306 
chr12:111505708-113105952 
chr12:111681897-112225304 
chr16:53539509-54185787 
chr18:57727147-58094636 
chr3:122976919-123206919 
chr3:123039584-123139034 
 
Table 7.  GWAS Catalog traits with genetic associations in Metabochip regions. I identified 
variants in the GWAS Catalog that were contained within Metabochip regions, and then filtered 
these down to a subset of associations with sufficient data to examine in this dataset.  Here, I 
provide the trait as described in the GWAS Catalog, the EHR-implementation of that trait, and 
the Metabochip region to which it corresponded.  In the case of lab values marked with an 
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asterisk, the median value was taken. In the case of values marked with a double asterisk, the 
median of yearly medians was taken. 
 
 I next investigated whether nearby transitions in local ancestry influenced the effects of 
these variants, as previously described. In Figure 20, the significance of all terms across 
Metabochip region chr6:25235303-26141375 with mean corpuscular hemoglobin (MCH) is 
provided as an example. I identified five significant interactions between local ancestry 
transitions and the allele across all traits, using a region-phenotype specific Bonferroni multiple 
testing correction.  I first visually characterized these interactions, grouping chromosomes 
together based on their local ancestry, allele, and local ancestry transition status. From this, it is 
apparent that two interactions (one between the variant rs9467458 and creatinine levels, the other 
between rs4712930 and white blood cell (WBC) counts) are driven by chromosome 
combinations that are rarely observed (i.e., have low cell counts) (Figure 21).  With so few 
observations, it is difficult to discern whether the chromosome category actually has an effect on 
the phenotype, or whether the individual with that chromosome category happens to fall on an 
extreme end of the normal phenotypic distribution for other reasons. This is evidenced by their 
lack of specific chromosome categories that are significant (Figure 21). The interaction between 
the variant rs1410438 and CO2 levels has a sufficient number of chromosomes in each category, 
and multiple chromosomes with a local ancestry transition seem to contribute to the significance 
of the interaction; however, it does not appear to be relevant whether the local ancestry transition 
is upstream or downstream of the variant (Figure 21).  This is suggestive of the transition itself, 
rather than any interaction with local ancestry, driving the effect. The two remaining interactions 
do have low numbers of chromosomes that meet the criteria for some categories; however, 
categories with low cell counts closely resemble the sample median and are not driving the trend. 
Consequently, two interactions remain promising and are further investigated. 
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Figure 20. The association of genetic variants and local ancestry to MCH. The variant 
rs1800562 (location marked by gray line in A) has been associated with a variety of iron-related 
phenotypes, and is located on a region of chromosome six that was densely genotyped on the 
Metabochip platform. I tested all the variants within this region for association with MCH using 
a linear regression model, in which I included covariates (top three principal components, age at 
measurement, and gender) and terms for the allele, local ancestry, presence of a local ancestry 
A. 
B. 
C. 
D. 
E. 
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transition in the region, and an interaction between the allele and local ancestry transition 
(Methods). The Manhattan plots for these terms are provided in A-D (note the difference in 
scale), respectively.  The specific local ancestry transitions observed in this region are shown in 
E. Dark green indicates European ancestry along the chromosome; light green indicates African 
ancestry. 
 58 
 
Figure 21. Interactions between local ancestry transitions and variants regulating 
creatinine, white blood cell counts, and CO2 levels.  For each significant interaction between 
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local ancestry transitions and a variant, I characterized the interaction by stratifying 
chromosomes based on: the local ancestry at the variant (EUR or AFR); whether they had the 
major or minor allele; whether there was a local ancestry transition on that chromosome within 
the broader Metabochip region, and if so, whether it occurred after (i.e., downstream) or before 
(i.e., upstream) of the variant.  The number of chromosomes in each category is additionally 
provided.  I conduced pairwise Mann Whitney U tests, comparing each category to the remainder 
of the sample, to determine significance.  Categories significantly different (p < 0.05) are shown 
in blue. The overall median is shown in red. The interaction between variant rs9467458 and local 
ancestry transitions to influence creatinine levels (A) is driven by a single chromosome of 
European ancestry, with the minor allele, and a downstream local ancestry transition. This 
chromosome category, while the most significant, does not significantly differ from the rest of 
the sample (p = 0.087). The interaction between variant rs4712930 and local ancestry transitions 
to regulate white blood cell (WBC) counts is attributable to three chromosomes with African 
ancestry, the minor allele, and an upstream ancestry transition. Again, while the most significant 
chromosome category, it is not significant (p = 0.051). Given the small cell counts, these are not 
further investigated.  The interactions between variant rs1410438 and local ancestry transitions 
associated with CO2 levels (C), while not due to low cell counts, does not have a clear biological 
interpretation.  Two chromosome categories, highlighted in blue, are significantly different (p < 
0.05) from the rest of the categories.  
rs16890640 interacts with local ancestry transitions to influence red blood cell traits 
 
We further investigated the two remaining interactions between local ancestry transitions and the 
allele to better understand the biological mechanisms underlying them. These two interactions 
identified the same variant, rs16890649, as interacting with a local ancestry transition to 
influence both MCH and mean corpuscular volume (MCV). These two phenotypes are highly 
correlated with one another, and consequently, the interactions strongly resemble one another. 
As shown in Figure 22, individuals with the variant on a European background and a 
downstream local ancestry transition have markedly lower MCH/MCV than any other 
combination. I further stratified these individuals on the basis of where their local ancestry 
transition occurred. There is a position-dependent effect wherein individuals with a local 
ancestry transition at the closest transition point (bp: 25481231) had lower MCH than did 
individuals with either of the two more distant transitions points (Figure 23). This suggests that 
the functional element that rs16890649 is putatively interacting with is located between 
rs16890649 and the second transition point. 
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Figure 22. Chromosomes with the minor allele for rs16890649 on a European background 
and a downstream local ancestry transition are associated with lower MCH and MCV.  To 
better understand the interactions for MCV (A) and MCH (B), I stratified chromosomes based 
on: the local ancestry at rs16890649 (EUR or AFR); whether they had the major or minor allele; 
whether there was a local ancestry transition on that chromosome within the broader Metabochip 
region, and if so, whether it occurred after (i.e., downstream) or before (i.e., upstream) of the 
variant.  The count row provides the number of chromosomes observed in each category.  
Individuals with a chromosome that: has the minor allele of rs16890649 on a European 
background with a downstream local ancestry transition have lower MCH and MCV levels than 
the sample median (indicated by the red line).  To determine which chromosome categories were 
driving the interaction, I performed a Mann Whitney U test comparing each chromosome 
category against the rest of the population; all significant interactions (p < 0.05) are in blue.  
Only one chromosome category was significant with multiple testing corrections for each 
pairwise test: the minor allele of rs16890649, on a European ancestry, with a downstream local 
ancestry transition for MCH (p = 0.0024).  
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Figure 23. The effect of downstream local ancestry transitions on MCH is position-
dependent.  There were three possible points at which downstream local ancestry transitions 
occurred (Figure 20). Individuals with the transition point at chr6:25481231 had the lowest 
average MCH levels. Individuals with transitions at the two subsequent transition points began to 
approach the median MCH level, which is shown in red. The number of chromosomes with 
European ancestry, the variant, and a local ancestry transition at each of these locations is 
provided above each boxplot. The MCH levels were not significantly different (p > 0.05; Mann 
Whitney U test) from one another; however, this is likely due to the small number of 
chromosomes with transitions at the later points. 
 
To better understand the biological mechanism mediating this interaction, I annotated this 
variant.  First, it is roughly three times more common in European-descent populations (CEU = 
23%) than it is in African-descent populations (YRI = 7%). It occurs within an intron of 
LRRC16A, which encodes a cytoskeleton-associated protein involved in regulation of actin 
polymerization; it is also associated with platelet development and production. rs16890640 is an 
eQTL for LRRC16A in whole blood, although it is not predicted to be an enhancer based on 
histone-modification patterns. However, the variant does fall within an observed binding site for 
a relevant transcription factor MAFK (Figure 24); when knocked out in mice, this transcription 
factor results in reduced MCV and MCH levels155. Additionally, it is less than 500 base pairs 
upstream of a predicted insulator element (Figure 24); however, chromatin looping patterns 
indicate that contacts occur on either side of this putative insulator (Figure 25). Thus, 
rs16890640 occurs within a plausibly relevant genomic-region, and is more frequent in 
Europeans.  
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Figure 24. Ancestry-specific recombination hotspots may disrupt functional elements 
pertinent to MCH and MCV. rs16890640 (highlighted in orange) is located within binding 
sites for MAFF and MAFK in HEPG2. Additionally, it occurs approximately 500 base pairs 
upstream of a predicted insulator element. This variant interacts with a downstream local 
ancestry transition, which likely occurs at one of the two recombination hotspots shown here. 
The first is shared between populations, whereas the second is specific to YRI, an African 
population. This recombination peak is in close proximity to rs2274089 (highlighted in purple), a 
GWAS catalog variant for related traits, and overlaps the next insulator element in GM12878. 
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Figure 25. Local ancestry transitions may perturb chromatin looping patterns within the 
region. The genomic region containing the African-specific recombination peak physically 
interacts with the promoter of LRRC16A based on ChIA-PET data for RAD21 in GM12878. The 
GWAS variant rs2274089, associated with a relevant phenotype, is highlighted in orange. 
 
 
I next investigated why this variant might interact with a downstream local ancestry 
transition to influence MCH and MCV levels.  I identified a relatively close (within 20kb) 
GWAS-catalog variant associated with a related phenotype, serum transferrin levels (i.e., the 
amount of glycoproteins that bind free iron). This suggests that the genomic region may be 
functionally important for MCH and MCV as well. Notably, this variant, rs2274089, is flanked 
by the two recombination peaks that could result in a local ancestry transition in the area of 
interest (Figure 24). The first of these recombination peaks is observed in both European (CEU) 
and African (YRI) descent populations; however, the second recombination peak is African-
specific.  This African-specific recombination peak overlaps a predicted insulator element 
(Figure 24), although this ChromHMM prediction is based largely on the presence of CTCF 
binding. Chromatin looping data and gene expression data suggest this region may be an 
enhancer: the region contacts the LRRC16A promoter in GM12878 (Figure 25), and the variant 
rs2274089 is an eQTL for LRRC16A in whole blood. Regardless of whether the region is an 
enhancer or insulator, it is clearly engaged in regulatory chromatin looping and is pertinent to 
related phenotypes.  
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As elaborated on more fully in the Discussion, I hypothesize that the African-specific 
recombination site introduces novel genetic variants that disrupt the regulatory functions of this 
genomic region, that then permit the European variant rs16890640 to engage in ‘off-target’ 
effects. 
 
PheWAS approach does not identify significant interactions between local ancestry transitions 
and EHR-derived phenotypes 
 
The GWAS Catalog is an incomplete representation of phenotype-genotype associations: there 
are many health-relevant phenotypes for which GWAS have not been performed, but which are 
available in the EHR, and there are many phenotypes in the GWAS Catalog that have not been 
investigated in an African American population. I performed a phenome-wide association study, 
or PheWAS, to determine if Metabochip regions harbored any novel associations. Consequently, 
I initially performed a standard single-marker association analysis that did not incorporate local 
ancestry information. I did, however, restrict my analysis to Metabochip regions with at least 200 
local ancestry transitions as my ultimate goal was to investigate interactions between local 
ancestry transitions and alleles. Following quality control steps (MAF > 5%; LD-pruned at r2 > 0.9), 
this left 2,856 variants with local ancestry assignments for analysis. None of the associations 
identified in the PheWAS passed either a Bonferroni multiple testing correction or a false 
discovery rate threshold of 10%. However, 168 phenotype-genotype associations were nominally 
significant (p < 5x10-5). Using the previously described methodology, I investigated whether 
local ancestry transitions interacted with the allele to influence the phenotype for these nominal 
associations (Table 8) (Full details are available in the Appendix: Nominal PheWAS associations 
do not interact with local ancestry transitions to influence phenotypes). Only one interaction 
passed a Bonferroni-multiple testing correction; however, further investigation revealed that it 
was attributable to low cell counts. Thus, only nominal genetic associations were identified, and 
these variants did not interact with local ancestry transitions significantly.   
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Phecode Description Variant Variant 
p-value 
Variant*Local 
ancestry 
transition p-
value 
480.5 Bronchopneumonia and lung 
abscess 
rs17641977_G 2.16E-05 2.42E-06 
707.1 Decubitus ulcer chr16.52362593_G 2.34E-06 7.97E-04 
250.13 Type 1 diabetes with 
ophthalmic manifestations 
chr6.25733715_G 1.45E-05 1.51E-03 
204.4 Multiple myeloma chr1.109619786_G 8.62E-06 1.11E-02 
614.1 Pelvic peritoneal adhesions, 
female (postoperative) 
(postinfection) 
chr7.14901079_G 8.18E-06 1.61E-02 
440 Atherosclerosis rs2744238_G 3.86E-05 1.98E-02 
276.11 Hyperosmolality and/or 
hypernatremia 
chr1.160348446_A 2.95E-05 2.91E-02 
270.3 Disorders of plasma protein 
metabolism 
chr7.14760490_G 1.56E-05 3.20E-02 
647.1 Infections of genitourinary 
tract during pregnancy 
chr16.52588027_A 1.43E-06 3.87E-02 
331.9 Cerebral degeneration, 
unspecified 
chr13.109701508_G 3.24E-05 4.59E-02 
628 Ovarian cyst chr7.14566856_G 4.18E-05 5.13E-02 
 
 
Table 8. Top associations from PheWAS for interactions between local ancestry transitions and 
alleles. I examined whether variants nominally associated (p < 5x10-5) in the PheWAS interacted 
with local ancestry transitions to influence the associated phenotype.  The top ten results from 
this analysis are reported here, the rest are in Appendix A. While one interaction passed the 
Bonferroni multiple testing correction for the interaction analysis, it was driven by a single 
chromosome (i.e., low cell counts) and was not considered further. 
 
Discussion 
 
In this Chapter, I hypothesized that ancestry-variable recombination events would disrupt the 
haplotype boundaries typically observed, thereby enabling the detection of epistasis within 
haplotypes. I investigated this in almost ten thousand African American adults, with both EHR-
derived phenotypes and genetic data on the Metabochip.  I first sought to identify significant 
genetic associations to phenotypes around which the Metabochip was designed; however, these 
European-based associations did not generalize to African American populations, despite our 
study being well-powered to detect reported effect sizes.  To investigate epistasis within 
haplotypes, I then examined whether alleles interacted with nearby local ancestry transitions to 
influence these phenotypes, and found little support. However, when I performed the same 
analysis for associations that had been originally identified in African-descent population, I 
found an interaction between a variant and a nearby local ancestry transition. This suggests that 
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combinations of genomic regions from differential continental ancestries may interact with one 
another to influence health traits in humans. 
 A variety of potential biological mechanisms exist through which this might occur.  In 
the case of the interaction I identified, I hypothesize that events frequent in one continental 
population can each alter local regulatory events, and that when in combination with one another, 
influence a clinical phenotype.  Specifically, the variant rs16890640 was associated with reduced 
MCV and MCH levels when it occurred on a European background and there was an immediate 
downstream local ancestry transition. The variant was roughly three times more frequent in 
Europeans, and it may have a regulatory effect as it both occurs within observed binding sites for 
trait-relevant transcription factors and is an eQTL.  The transition could occur at either a hotspot 
shared between populations or at one specific to African-descent. These potential recombination 
sites flank a GWAS Catalog variant for a related trait, illustrating the phenotypic-relevance of 
the genomic region. The region also is densely annotated for regulatory function, and engages in 
chromatin looping to nearby promoters. I hypothesize that the African-specific recombination 
hotspot, which overlaps putative insulators, is introducing low-frequency genetic variants that 
alter its function.156 When this occurs, the regulatory variant rs16890640 is then able to engage 
in ‘off-target’ effects, which ultimately reduce MCH and MCV levels.  For example, the 
regulatory region could interact with HFE, a gene approximately 600 kb away that regulates iron 
uptake.157,158  Mutations in this gene cause hereditary haemochromatosis, wherein excess iron is 
deposited within organs, ultimately leading to their failure.159 To investigate this hypothesis, I am 
first examining whether there are such disruptive variants at the African-specific recombination 
peak.  There are also other possible explanations: regardless of recombination-induced 
mutagenesis, an African haplotype may simply be carrying a variant that interacts with 
rs16890640 to influence MCH and MCV. However, it is less clear whether downstream elements 
directly relate to MCH or MCV levels. Ultimately, functional validation of any hypotheses – 
such as examining whether chromatin looping is altered – will be required to discern between 
possibilities. 
The interaction I identified provides potential evidence for epistasis influencing health-
related phenotypes in humans. The variant rs16890640 is not significantly associated with the 
phenotype on its own – it is only in combination with the downstream transition to African 
ancestry that an association to the phenotype is observed.  While it is possible that this 
combination of events somehow is tagging a causal variant within this region, I consider this 
unlikely as nearby variants did not demonstrate a strong association. Instead, it highlights that 
admixed populations provide a unique opportunity to investigate epistasis, as novel combinations 
of variants are generated and unique population-specific recombination hotspots may disrupt 
functional haplotypes.  
 That I identified only a single interaction between a variant and local ancestry transitions 
should not be taken as evidence that these events are rare due to several limitations of our study.  
First, the Metabochip is a custom genotyping array specifically designed to capture variation 
within specific genomic regions; it is not a genome-wide platform. Thus, I only investigated a 
subset of the local ancestry transitions that occur within the whole genome. Additionally, it 
should be recognized that while EHRs provide a wealth of medical information, they are often 
incomplete representations – not all diagnoses may be contained within a patient’s EHR, 
especially when Vanderbilt Hospitals are not the patient’s source of primary care. In some cases, 
this may result in actual cases being considered controls. While this should not result in spurious 
associations, it would reduce our power to detect effects. Finally, all local ancestry transitions 
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were treated the same in this study, regardless of where they occurred, or whether it was from 
European to African, or vice-versa. I grouped the transitions together due to their general 
infrequency; however, this may have diluted signal originating from specific combinations. 
Consequently, interactions between variants and local ancestry transitions may be a more 
frequent mechanism influencing health-related phenotypes. 
 An additional limitation was the lack of robust genetic associations within this region, 
regardless of local ancestry transitions.  Given that these regions largely contained variants with 
significant associations in the GWAS Catalog, we were initially surprised by the lack of robust 
signal.  However, studies generalizing associations between European and African descent 
populations have had mixed success thus far.  Many find that while the direction of effect may be 
consistent between populations, the significance of this effect is influenced by differential LD 
structure with the causal variant, frequency differences between populations, and sample 
size.154,160–162 As a consequence, a notable proportion of variants fail to generalize between 
populations when significance of the association is the primary metric, which we used in this 
analysis.162,163 While this may account for the lack of generalization of signals between 
populations, the major issue for our study is the lack of robust associations, rather than the 
generalization of associations, as it obfuscates the interpretation of negative results. It is unclear 
in many cases whether local ancestry transitions do not interact with the variant to influence the 
phenotype, or whether the region is unrelated to the phenotype in African Americans.   
 There are several avenues I wish to explore in the future.  First, it is critical to replicate 
the interaction we identified in an additional dataset. I am currently examining the feasibility of 
doing so in either Geisinger or the eMERGE network.  Also, I wish to implement statistical 
approaches designed to pinpoint precisely what element the variant rs16890640 is interacting 
with to influence MCH and MCV, such as testing combinations of variants within the 
recombination region for epistasis with rs16890640.  Our hypothesis that genetic variants of 
different continental ancestries may also be investigated more broadly; for instance, instead of 
focusing on local ancestry transitions on a chromosome, complete genotyping or sequencing data 
would enable the investigation of differential local ancestry combinations in biological pathways.  
Similarly, differences in ancestry between the mitochondria or Y-chromosome and autosomal 
regions may be relevant. Finally, investigation of this hypothesis between three-way admixture 
populations, such as Hispanics, may improve power to detect effects, as local ancestry transitions 
are likely to be more frequent. 
 Here, I propose a mechanism in which genetic variants from different continental 
ancestries, when combined in admixed populations, result in phenotypic associations not 
otherwise observed. I identified a specific interaction in which this appears to occur, however 
this mechanism is general: it could apply to many phenotypes, all admixed populations, and may 
encompass other sorts of continental ancestry combinations, such as mitochondrial/Y-
chromosome with autosomal regions, or regions within biological pathways.  It highlights the 
need to perform genetic ancestry studies within admixed populations (as the variants may not 
have an effect in either continental population) in order to address health disparities, and the 
potential role of epistasis in human health. 
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CHAPTER 4 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
 
In this work, I developed a set of best practices for the study of statistical epistasis, and 
investigated whether there was evidence for regulatory epistasis in humans in two distinct 
biological contexts.  In Chapter 2, I first developed a set of quality control procedures to identify 
statistical interactions likely attributable to biological epistasis, rather than confounding 
processes. I then investigated whether cis-regulatory variants interact to regulate gene expression 
levels, a quantitative low-level phenotype, in cell lines, where environmental factors are kept 
constant.  Once confounding explanations were addressed, I found little evidence for epistasis 
between cis-regulatory variants influencing gene expression levels.  In Chapter 3, I investigated 
epistasis in admixed populations, under the hypothesis that ancestry-specific recombination 
hotspots may break apart haplotypes, thereby enabling the detection of epistasis. In contrast to 
molecular phenotypes examined in Chapter 2, the majority of phenotypes I investigated here 
were complex, EHR-derived phenotypes. I identified a promising interaction between a variant, 
and a downstream local ancestry transition, that influenced red blood cell traits.   
Overall, our results suggest that when rigorous statistical criteria are applied, interactions 
with a moderate effect size between common, unlinked variants are either uncommon at the 
population level across a broad range of phenotypes, or are not detectable by our approach.  On 
the surface, this appears to contradict both studies in model organisms, where epistasis is 
pervasive, and findings from massively parallel reporter assays. Here, I reconcile these findings, 
and make recommendations for the future study of epistasis based on the consensus of these 
bodies of literature. 
 
Reconciliation with findings from model organisms  
 
Evidence from model organisms indicates that epistasis accounts for a notable component of 
phenotypic variance in yeast1, Drosophila2,27, and mouse30 – yet I found little evidence for 
epistasis in humans.  There are several differences in both the genetic architecture of model 
organisms and in the experimental approach taken by these studies that may both account for this 
discrepancy and shed light on future approaches for the study of epistasis in humans. 
First, there is frequently a fundamental difference in the scientific question being 
addressed between studies of epistasis in model organisms versus those generally conducted in 
humans.  Studies in model organisms often quantify the overall effect of epistasis across the 
genome, whereas I sought to identify specific pairs of interacting elements.  This is analogous to 
comparing the amount of phenotypic variance attributable to additive effects in a heritability 
study to the amount of phenotypic variance explained by variants identified in a GWAS. To 
provide a more appropriate comparison to model organisms, future studies of epistasis might 
consider heritability analyses capable of partitioning phenotypic variance into non-additive 
genetic components. Studies of epistasis in model organisms that seek to identify specific 
interacting variants are more analogous to human-based studies; in yeast, they typically find that 
the interactions have smaller effect sizes than those observed for single variants.1 Bloom et al. 
found that the largest epistatic effect was approximately a fifth of the size of the largest additive 
effect for variants influencing gene expression levels.1 I was underpowered to detect smaller 
effect sizes in both Chapters 2 and 3 (Tables 2 and 6). Therefore, findings in both bodies of 
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literature would be consistent with large numbers of small-effect interactions that account for the 
majority of phenotypic variance attributable to epistatic effects. 
An alternative, and not necessarily exclusive, explanation is that I investigated epistasis 
on a different scale than that used in many model organism studies. I specifically investigated 
epistasis between variants proximal to one another, either within the same cis-regulatory region 
or in specific genomic regions densely genotyped by Metabochip. In contrast, studies of model 
organisms often quantify epistasis on the chromosomal level,30 or between genes on different 
chromosomes.7,8  Thus, epistasis may be occurring primarily between distant genomic elements, 
which are frequently referred to as gene by gene interactions.  Comprehensive studies of 
pairwise interactions between such distal variants incur a steep multiple testing correction, and 
thus have limited power to detect effects in sample sizes typically used in genetic association 
studies.80  Careful filtering of the pairs tested based on biological knowledge, such as pathways 
or protein-protein interactions, may preserve power by reducing the number of associations 
tested. 
Finally, model organisms generally have a more homogenous genetic background than 
natural populations. This reduces the phenotypic ‘noise’ attributable to other genetic variants in 
the genome, and thereby improves power to detect associations.  In contrast, the increased 
genetic diversity within natural populations such as humans results in greater phenotypic 
variance and reduced power to detect effects. There are population isolates – such as the Amish – 
that are more homogenous both genetically and culturally than are many other populations.  
Investigation of epistasis in population isolates may therefore improve power to detect effects.  
Ultimately, the conclusions drawn from animal studies and those presented in this work 
are consistent with one another.  And while minimal evidence for epistasis was found in 
Chapters 2 and 3, the approaches used in model organisms highlight potential ways to move the 
study of epistasis in humans forward – largely through statistical methods that are capable of 
capturing aggregate effects, investigation of gene by gene interactions, and/or the usage of 
population isolates with homogeneous genetic backgrounds.  
 
Reconciliation with findings from massively parallel reporter assays 
 
In addition to model organisms, massively-parallel reporter assays have been used to study 
epistasis for human regulatory sequences with engineered mutations. Kwasnieski et al. found that 
the majority of double mutants showed evidence of epistasis influencing the regulatory function 
of the Rhodopsin promoter.78 This is most closely analogous to the interrogation of epistasis 
between cis-regulatory variants in Chapter 2, and draws markedly different conclusions. Several 
methodological differences may account for these discrepancies. 
First, Kwanieski et al.78 engineered genetic variation, rather than relying on observed genetic 
variation within the natural population.  Additionally, they only investigated effects within a 
single cis-regulatory sequence. Thus, while their results neatly demonstrate the potential for 
epistasis within the cis-regulatory region, they cannot be taken as a measure of how common 
such interactions may be.  Secondly, they engineered genetic variants within a 52 base pair 
window, meaning that most variant combinations tested were in very close proximity to one 
another. In contrast, common genetic variants in human populations are found approximately 
every 300 base pairs. Even if common variants were in such close proximity to one another, it is 
unlikely that a recombination event would occur in the limited space between these variants such 
that they are broken apart.  Thus, scenarios described by Kwasnieski et al.78 would most likely 
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occur within haplotypes in natural populations. As discussed in Chapters 2 and 3, without all 
possible genotype combinations present regression-based techniques are unable to detect 
epistasis.  Finally, the ability to detect effects within a reporter assay is in no way dependent on 
the frequency of the alleles within the population. In contrast, the power to detect effects in 
Chapters 2 and 3 was intimately tied to the frequency of the allele-combinations within the 
population.  
 Ultimately, Kwasnieski et al. found that engineered variants within a cis-regulatory 
region interact with one another the majority of the time; however, their results do not shed light 
on how frequently such combinations of variants actually occur within the natural population. 
Additionally, their findings indicate that epistasis within this region is likely to occur within 
haplotypes, or between rare variants. In these situations, reporter assays may be ideal 
methodological approaches to detect regulatory epistasis. 
 
Where is epistasis? 
 
We conclude that epistasis is a component of the genetic architecture in humans – the debate is 
over where it occurs, and how much phenotypic variation it accounts for. I demonstrate in 
Chapters 2 and 3 that interactions with large effects between common, unlinked variants in 
proximal regions are likely uncommon. This is consistent with analogous studies in model 
organisms and is not contradicted by results from massively parallel reporter assays. Based on 
both our results and these bodies of literature, I propose that epistasis is primarily based on 
small-effect interactions, or occurs in the following contexts: within haplotypes, as suggested by 
Kwasnieski et al.78 and Corradin et al.126; between uncommon variant combinations; or between 
distant regions, as shown repeatedly in model organisms.7,8,30 These explanations are not 
inherently exclusive; for example, distal interactions may have small effect sizes.  I recommend 
that future studies of epistasis investigate it within these contexts.  
 
Association-based methods may be ill-suited for future studies of epistasis 
 
Standard association tests that use regression to detect relationships between genotypes and 
phenotypes rely on genetic diversity within natural populations to detect epistasis, and may be 
ill-suited to detect epistasis in the above situations. First, they require that all nine possible 
genotype combinations be represented within the sample in order to accurately partition 
phenotypic variance amongst genetic components.  In the case of both haplotype effects and rare 
variants, this is unlikely to occur.  Secondly, the power to detect effects in such studies is a 
function of five factors: allele frequencies, LD between variants, effect size, sample size, and the 
number of association tests performed.  Researchers cannot alter either allele frequencies, LD 
patterns, or the effect size; thus, the only way to improve power is either to increase sample size 
or to reduce the number of association tests.  To comprehensively investigate trans-interactions 
(i.e., gene by gene interactions), the number of association tests increases dramatically, as does 
the multiple testing correction; Hemani et al. conducted such a study, and faced a multiple 
testing correction threshold of 2.91x10-16.80  Thus, investigating either small-effect interactions 
or trans- interactions comprehensively will require an increase in sample size above and beyond 
that required by standard GWAS. While many factors influence the power to detect epistasis, 
even the best of circumstances (i.e., common, unlinked variants) will require sample sizes of 
approaching 75,000 to be well-powered to detect modest effect size interactions (Table 9). Thus, 
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the utility of association-based approaches to detect epistasis is limited by its reliance on 
naturally occurring genetic variation within a population, pervasive confounding influences, and 
a limited power to detect effects. 
 
MAF Variant 1 MAF Variant 2 Cases Controls Power 
0.05 0.05 300,000 350,000 0.76 
 0.25 70,000 100,000 0.80 
 0.5 40,000 110,000 0.81 
0.25 0.25 15,000 50,000 0.75 
 0.5 11,500 50,000 0.79 
0.5 0.5 10,000 50,000 0.80 
 
Table 9. Sample sizes required for adequate power to detect small effect interactions or 
trans-effects. Here, I estimate the sample sizes required to detect epistasis assuming simplified 
models (i.e., no linkage between variants) and a Bonferroni multiple testing correction of 1.0x10-
14, which is more lenient than the threshold used for a comprehensive analysis of epistasis 
genome-wide.80 I assumed only an effect of the interaction (odds ratio = 1.2), without marginal 
effects of the variants. Approximations were made using the QIMR’s Epistasis Power Calculator 
(https://gump.qimr.edu.au/general/manuelF/epistasis/epipower4i.html). 
 
  
Alternative approaches to the study of epistasis 
 
Alternative methods are required to identify epistasis in haplotypes, between rare variants, with 
small effect sizes, or between distant variants.  Below, I make recommendations on how to 
approach the study of epistasis in these contexts.  
 Detection of epistasis on a haplotype requires that it be broken, such that the effect of 
each variant individually can be quantified and compared to the joint effect. This can be 
accomplished by either synthesizing sequences, as was done by Kwasnieski et al.78, or through 
genome-editing approaches such as CRISPR. Once the required combinations of genetic 
variation have been generated, a functional assay is required to measure their effect.  In the case 
of regulatory sequences, this can be readily accomplished through reporter assays. For coding 
variants within the same gene, epistasis has been quantified through comparing changes in 
Gibbs’s free energy,65–67 other thermodynamic properties, or the predicted 3D structure. For 
coding variants in different genes, epistasis between variants within protein-protein interfaces 
has been biochemically assayed to determine if they disrupt binding.68  Ultimately, investigation 
of epistasis within haplotypes will be best accomplished through methods that can create all 
combinations of the observed variants, and then have a high-throughput assay to measure the 
phenotypic effect. 
 Detection of epistasis between rare variants can be best accomplished when power to 
detect effects is not contingent on the frequency within the population.  This can be 
accomplished through two major methodological approaches: family-based studies and 
functional assays such as those just described. Family studies would be best suited for the study 
of epistasis between variants distant from one another, as recombination unlikely to break apart 
variants in close proximity to one another (i.e., haplotypes).  Functional assays that rely on either 
synthesized or edited sequences, however, could be amenable to either cis- or trans-interactions.  
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Thus, the investigation of epistasis involving rare variants is likely not best accomplished within 
the general population, but rather through the usage of families or high throughput functional 
assays.  
 Detection of epistatic interactions with small-effect sizes is mostly impeded by lack of 
power.  There are two possible ways to circumvent this issue – methods that look for the 
aggregate effect of epistasis genome-wide, rather than individual effects, and methods that 
improve power.  First, methods such as genome-wide complex trait analysis (GCTA) quantify 
the phenotypic variance attributable to additive genetic effects; however, this method can be 
expanded to partition phenotypic variance to non-additive effects such as epistasis. This 
approach would be especially useful, as it would indicate the extent of epistatic effects that could 
be anticipated under ideal circumstances. Secondly, there are ways in which power can be 
improved – namely, reducing the number of association tests or changing attributes of the 
sample.  Thus, small-effect epistasis could be investigated using current association-based 
approaches; however, this would be possible for only a limited number of pairs of variants.  By 
investigating epistasis in population isolates, which have reduced phenotypic noise, small-effect 
epistasis could be examined more comprehensively.  Ideally, I recommend a two-step approach 
to the investigation of small-effect epistasis: first, quantify the aggregate effect; secondly, 
perform a targeted analysis of specific pairs of variants. 
 Finally, detection of epistasis between variants on different chromosomes, i.e. gene by 
gene interactions, is limited by power to detect effects in the face of numerous association tests.  
Approaches that are able to use biological knowledge – such as pathways, or protein-protein 
interactions – to prune down the number of association tests may increase the likelihood of 
identifying epistasis; however, they are limited by a priori knowledge and cannot address the 
extent of epistasis.  Alternatively, the number of association tests performed could be reduced by 
collapsing genetic variants into a single variable.  For instance, a collapsing or burden score 
could indicate whether there were any variants within a gene predicted to have deleterious 
effects.164–169 Then, all pairwise combinations of genes could be investigated for epistatic effects. 
This could be applied to a specific phenotype or, pending the availability of EHR data, to a 
PheWAS. Alternatively, data from chromatin conformation capture (e.g., 3C) approaches could 
be used to identify genomic regions in physical contact with one another, and epistasis could be 
investigated between these regions specifically.  Overall, the interrogation of trans-effects is 
unlikely to be able to quantify the prevalence of epistasis genome-wide; however, careful 
selection of variants may enable the detection of epistasis in specific contexts. 
 Ultimately, the study of epistasis still has the potential to shed light on the biological 
mechanisms underlying complex disease in humans; however, it is critical that it be carefully 
investigated.  In Chapter 2, I demonstrate that the quality control procedures sufficient for single-
variant association analysis do not address rampant confounding influences.  In Chapters 2 and 3, 
I demonstrate that common, cis-regulatory variants do not interact with one another with effect 
sizes anticipated based on single-variant analyses. Thus, both the biological expectations and 
statistical methodologies sufficient for single-marker analyses are not suited for the study of 
epistasis. Instead, the approaches which I outlined above are more likely to identify epistasis 
where it likely resides – within haplotypes, between rare variants, in interactions with small 
effects, or between distant variants. 
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APPENDIX 
 
 
A. Nominal PheWAS associations do not interact with local ancestry transitions to 
influence phenotypes. 
I performed a PheWAS to identify potential genetic associations within Metabochip regions not 
represented in the GWAS Catalog.  While no associations passed a Bonferroni multiple-testing 
correction threshold, 168 variants were nominally significant (p < 5x10-5).  These associations 
are reported below. I then examined whether these variants interacted with local ancestry 
transitions (Methods) to influence the associated phenotype.  The results are sorted based on the 
significance of the interaction p-value.  While one interaction passed the Bonferroni multiple 
testing correction for the interaction analysis, it was driven by a single chromosome (i.e., low 
cell counts) and was not considered further. 
 
 
Phecod
e 
Description Variant Variant 
p-value 
Variant*Loca
l ancestry 
transition p-
value 
480.5 Bronchopneumonia and lung 
abscess 
rs17641977_G 2.16E-05 2.42E-06 
707.1 Decubitus ulcer chr16.52362593_G 2.34E-06 7.97E-04 
250.13 Type 1 diabetes with 
ophthalmic manifestations 
chr6.25733715_G 1.45E-05 1.51E-03 
204.4 Multiple myeloma chr1.109619786_G 8.62E-06 1.11E-02 
614.1 Pelvic peritoneal adhesions, 
female (postoperative) 
(postinfection) 
chr7.14901079_G 8.18E-06 1.61E-02 
440 Atherosclerosis rs2744238_G 3.86E-05 1.98E-02 
276.11 Hyperosmolality and/or 
hypernatremia 
chr1.160348446_A 2.95E-05 2.91E-02 
270.3 Disorders of plasma protein 
metabolism 
chr7.14760490_G 1.56E-05 3.20E-02 
647.1 Infections of genitourinary tract 
during pregnancy 
chr16.52588027_A 1.43E-06 3.87E-02 
331.9 Cerebral degeneration, 
unspecified 
chr13.109701508_
G 
3.24E-05 4.59E-02 
628 Ovarian cyst chr7.14566856_G 4.18E-05 5.13E-02 
578.2 Blood in stool chr13.109644522_
G 
3.62E-06 5.39E-02 
41.2 Streptococcus infection chr7.14250501_A 3.65E-05 5.57E-02 
669 Complications of labor and 
delivery NEC 
chr6.25453823_G 1.57E-05 6.36E-02 
781 Symptoms involving nervous 
and musculoskeletal systems 
chr7.14586312_C 1.17E-05 7.28E-02 
592.1 Cystitis rs10800394_G 1.21E-05 7.44E-02 
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710.12 Chronic osteomyelitis chr7.15045801_G 2.29E-05 7.55E-02 
427.9 Palpitations chr13.109782559_
G 
2.09E-05 8.43E-02 
348.8 Encephalopathy, not elsewhere 
classified 
chr11.2692602_A 2.37E-05 9.38E-02 
427.9 Palpitations chr13.109782978_
G 
5.51E-06 1.03E-01 
608 Other disorders of male genital 
organs 
chr7.14334642_G 4.39E-05 1.15E-01 
250.14 Type 1 diabetes with 
neurological manifestations 
chr16.52263655_A 4.53E-05 1.18E-01 
577 Diseases of pancreas chr1.160589579_A 4.81E-05 1.22E-01 
592 Cystitis and urethritis rs10800394_G 1.52E-05 1.26E-01 
994 Sepsis and SIRS chr6.25596244_A 2.63E-05 1.28E-01 
117.1 Histoplasmosis chr1.160477578_A 1.49E-05 1.38E-01 
539 Bariatric surgery chr7.14532220_C 7.97E-06 1.55E-01 
614.3 Pelvic inflammatory disease 
(PID) 
chr7.14585551_C 6.61E-06 1.55E-01 
627.22 Need for Hormone replacement 
therapy (postmenopausal) 
rs12340741_G 2.71E-05 1.57E-01 
285.21 Anemia in chronic kidney 
disease 
rs6456688_A 3.55E-05 1.58E-01 
704.2 Hirsutism chr13.109648374_
A 
3.95E-05 1.63E-01 
290.1 Dementias chr6.26230912_C 1.27E-05 1.66E-01 
769 Nonallopathic lesions NEC chr7.14163174_G 4.16E-05 1.67E-01 
601.3 Orchitis and epididymitis chr7.14548630_A 9.54E-06 1.70E-01 
245.2 Chronic thyroiditis chr13.109632419_
A 
6.93E-07 1.73E-01 
245.21 Chronic lymphocytic thyroiditis chr13.109632419_
A 
6.93E-07 1.73E-01 
707.1 Decubitus ulcer chr7.15035730_A 8.89E-06 1.73E-01 
740.1 Osteoarthritis; localized chr13.109679060_
G 
1.67E-05 1.75E-01 
614.54 Abscess or ulceration of vulva chr7.14337575_G 2.51E-06 1.75E-01 
242 Thyrotoxicosis with or without 
goiter 
chr16.52671149_A 1.46E-05 1.78E-01 
245 Thyroiditis chr13.109632419_
A 
4.70E-05 1.82E-01 
513.3 Hypoventilation chr7.14812267_A 3.79E-05 1.87E-01 
251 Other disorders of pancreatic 
internal secretion 
chr7.14820434_G 9.25E-06 1.89E-01 
473 Diseases of the larynx and vocal 
cords 
chr13.109805546_
A 
2.33E-05 2.02E-01 
274 Gout and other crystal chr13.109844573_ 2.72E-05 2.03E-01 
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arthropathies C 
769 Nonallopathic lesions NEC chr7.14162727_G 2.73E-05 2.04E-01 
204 Leukemia chr6.25517293_G 2.33E-05 2.10E-01 
149.4 Cancer of larynx chr13.109693401_
C 
2.67E-05 2.11E-01 
473 Diseases of the larynx and vocal 
cords 
chr13.109803476_
A 
2.68E-06 2.13E-01 
623 Hypertrophy of female genital 
organs 
chr11.2519713_A 3.23E-05 2.14E-01 
457 Encounter for long-term 
(current) use of anticoagulants, 
antithrombotics, aspirin 
chr16.52658019_G 3.69E-05 2.30E-01 
614.52 Vaginitis and vulvovaginitis chr16.52565323_C 1.40E-05 2.39E-01 
772.3 Muscle weakness chr13.109638381_
A 
1.18E-05 2.42E-01 
415.2 Chronic pulmonary heart 
disease 
chr16.52645735_A 8.46E-06 2.43E-01 
614.52 Vaginitis and vulvovaginitis chr11.2754881_G 2.85E-05 2.57E-01 
204 Leukemia chr16.52102494_G 2.54E-05 2.71E-01 
526 Diseases of the jaws chr16.52449474_A 2.39E-05 2.72E-01 
696.41 Psoriasis vulgaris chr13.109715932_
A 
2.22E-06 2.75E-01 
614.5 Inflammatory disease of cervix, 
vagina, and vulva 
chr16.52565323_C 4.73E-05 2.77E-01 
245.2 Chronic thyroiditis rs4721366_A 1.59E-05 2.82E-01 
245.21 Chronic lymphocytic thyroiditis rs4721366_A 1.59E-05 2.82E-01 
592 Cystitis and urethritis chr16.52109683_C 5.82E-06 2.83E-01 
245 Thyroiditis rs4721366_A 4.66E-06 2.89E-01 
473.4 Voice disturbance chr13.109803934_
C 
4.49E-05 2.92E-01 
433.8 Late effects of cerebrovascular 
disease 
chr13.109680753_
A 
3.94E-05 2.95E-01 
613.1 Inflammatory disease of breast chr7.15001772_A 3.02E-05 2.96E-01 
715.1 Sacroiliitis NEC chr13.109780358_
G 
1.92E-05 2.98E-01 
245.2 Chronic thyroiditis chr13.109621283_
G 
1.08E-05 3.00E-01 
245.21 Chronic lymphocytic thyroiditis chr13.109621283_
G 
1.08E-05 3.00E-01 
696.4 Psoriasis chr13.109715932_
A 
6.93E-06 3.03E-01 
696 Psoriasis and related disorders chr13.109715932_
A 
6.42E-06 3.12E-01 
592 Cystitis and urethritis chr1.160539069_A 4.09E-05 3.13E-01 
946 Anaphylactic shock NOS chr7.14390177_G 4.66E-05 3.16E-01 
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642.1 Preeclampsia and eclampsia chr16.52560791_G 3.34E-05 3.20E-01 
375.1 Dry eyes chr6.25764640_C 2.38E-05 3.25E-01 
334 Degenerative disease of the 
spinal cord 
chr13.109654095_
A 
3.91E-06 3.57E-01 
706.1 Acne chr6.25374688_A 2.34E-05 3.58E-01 
735.21 Hammer toe (acquired) chr6.25653929_G 2.26E-05 3.59E-01 
706.1 Acne chr6.25381901_T 4.07E-05 3.64E-01 
496.3 Bronchiectasis chr7.14420590_G 7.06E-06 3.65E-01 
225.1 Benign neoplasm of brain, 
cranial nerves, meninges 
chr16.52658905_A 6.47E-06 3.83E-01 
626.2 Dysmenorrhea chr7.15031313_A 2.44E-05 3.86E-01 
202.2 Non-Hodgkins lymphoma chr16.52743030_A 2.38E-05 3.89E-01 
585.33 Chronic Kidney Disease, Stage 
III 
chr9.135184633_A 1.29E-05 3.93E-01 
150 Cancer of esophagus chr6.25373969_A 6.54E-06 3.97E-01 
646 Other complications of 
pregnancy NEC 
chr1.160257615_G 2.72E-05 3.98E-01 
990 Effects radiation NOS chr11.2747784_A 2.94E-06 3.99E-01 
245 Thyroiditis chr7.14820824_A 4.66E-05 3.99E-01 
368 Visual disturbances chr16.52685380_A 4.05E-05 4.02E-01 
250.14 Type 1 diabetes with 
neurological manifestations 
chr7.14683390_A 2.27E-05 4.07E-01 
225.1 Benign neoplasm of brain, 
cranial nerves, meninges 
chr16.52658156_C 3.68E-05 4.14E-01 
614 Inflammatory diseases of 
female pelvic organs 
chr16.52565323_C 3.54E-05 4.18E-01 
225 Benign neoplasm of brain and 
other parts of nervous system 
chr16.52658905_A 2.68E-05 4.23E-01 
573.2 Liver replaced by transplant chr1.109762407_G 5.87E-06 4.40E-01 
642.1 Preeclampsia and eclampsia chr16.52566594_G 1.37E-06 4.46E-01 
635.2 Antepartum hemorrhage, 
abruptio placentae, and placenta 
previa 
chr1.160331877_G 4.98E-07 4.51E-01 
695.42 Systemic lupus erythematosus chr9.135125327_A 1.41E-05 4.67E-01 
578.2 Blood in stool chr13.109662438_
G 
5.27E-06 4.74E-01 
707.3 Chronic ulcer of unspecified site rs9295676_A 1.90E-05 4.86E-01 
377.3 Optic neuritis/neuropathy rs4784323_A 3.39E-05 4.87E-01 
745 Pain in joint chr1.160405816_A 4.82E-05 4.87E-01 
170.1 Bone cancer chr1.160435746_G 4.65E-05 4.88E-01 
281.9 Deficiency anemias rs16835127_G 9.91E-06 4.89E-01 
473.4 Voice disturbance chr13.109803476_
A 
6.23E-06 4.97E-01 
290 Delirium dementia and amnestic 
and other cognitive disorders 
chr6.26230912_C 3.24E-06 5.01E-01 
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512.7 Shortness of breath rs4395714_C 4.17E-06 5.04E-01 
635 Hemorrhage during pregnancy; 
childbirth and postpartum 
chr1.160331877_G 2.31E-05 5.19E-01 
285 Other anemias chr11.2891879_A 2.78E-05 5.22E-01 
202.22 Reticulosarcoma chr16.52743030_A 4.74E-06 5.23E-01 
592.1 Cystitis chr16.52109683_C 1.10E-05 5.32E-01 
513.3 Hypoventilation chr1.160272821_G 5.56E-07 5.40E-01 
681.2 Cellulitis and abscess of 
face/neck 
chr9.135280428_G 2.63E-05 5.45E-01 
368.4 Visual field defects chr6.25504869_A 8.24E-06 5.46E-01 
270.32 Paraproteinemia chr9.135300838_G 1.06E-05 5.48E-01 
296.1 Bipolar chr13.109604690_
A 
1.31E-05 5.50E-01 
593.1 Gross hematuria chr16.52331386_G 2.58E-05 5.50E-01 
772.1 Muscular wasting and disuse 
atrophy 
chr13.109638381_
A 
1.88E-05 5.52E-01 
536 Disorders of function of 
stomach 
chr7.14943393_A 1.70E-05 5.61E-01 
379.5 Disorders of iris and ciliary 
body 
chr1.160380841_A 2.88E-05 5.66E-01 
446 Polyarteritis nodosa and allied 
conditions 
chr11.2800624_G 1.17E-05 5.72E-01 
628 Ovarian cyst chr13.109650477_
A 
2.95E-05 5.77E-01 
506 Empyema and pneumothorax rs16835127_G 2.26E-07 5.82E-01 
635.2 Antepartum hemorrhage, 
abruptio placentae, and placenta 
previa 
chr1.160321867_C 2.55E-05 5.93E-01 
946 Anaphylactic shock NOS chr7.15032089_T 5.59E-06 5.93E-01 
496.3 Bronchiectasis chr6.25522825_A 6.37E-06 5.95E-01 
285.21 Anemia in chronic kidney 
disease 
chr7.14760490_G 2.36E-05 6.08E-01 
697 Sarcoidosis chr1.160272821_G 2.09E-05 6.12E-01 
288.3 Eosinophilia chr1.109538695_A 3.44E-05 6.32E-01 
560.1 Paralytic ileus chr1.160626500_A 4.25E-05 6.40E-01 
473.3 Paralysis/spasm of vocal cords 
or larynx 
chr7.14175664_G 9.28E-06 6.52E-01 
735.2 Acquired toe deformities chr6.25653929_G 4.82E-05 6.53E-01 
946 Anaphylactic shock NOS chr7.15022570_T 2.21E-05 6.73E-01 
280.2 Iron deficiency anemia 
secondary to blood loss 
(chronic) 
chr7.14294180_A 4.33E-05 6.80E-01 
540.11 Acute appendicitis chr16.52557265_G 2.29E-05 6.82E-01 
871.2 Open wound of finger(s) chr1.109509843_A 2.45E-05 7.07E-01 
530.1 Esophagitis, GERD and related chr7.14684017_A 4.20E-05 7.08E-01 
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diseases 
352 Disorders of other cranial 
nerves 
chr16.52611296_A 2.71E-05 7.08E-01 
357 Inflammatory and toxic 
neuropathy 
chr6.26206734_A 2.82E-05 7.15E-01 
348 Other conditions of brain chr13.109680753_
A 
4.01E-05 7.30E-01 
695.7 Prurigo and Lichen chr16.52713187_A 2.95E-05 7.34E-01 
446 Polyarteritis nodosa and allied 
conditions 
chr11.2797941_A 1.28E-05 7.52E-01 
389.2 Conductive hearing loss chr16.52713187_A 3.26E-06 7.55E-01 
721 Spondylosis and allied disorders chr11.2712577_A 3.19E-05 7.66E-01 
819 Skull and face fracture and 
other intercranial injury 
chr7.14351815_G 7.91E-06 7.73E-01 
963.1 Antineoplastic and 
immunosuppressive drugs 
causing adverse effects 
chr1.160491418_G 2.65E-05 7.77E-01 
530 Diseases of esophagus chr7.14684017_A 8.48E-06 7.79E-01 
446 Polyarteritis nodosa and allied 
conditions 
chr11.2803003_A 2.83E-05 7.80E-01 
579 Other symptoms involving 
abdomen and pelvis 
chr16.52681013_A 3.53E-05 7.83E-01 
457 Encounter for long-term 
(current) use of anticoagulants, 
antithrombotics, aspirin 
chr16.52657870_G 2.59E-05 7.90E-01 
727.4 Ganglion and cyst of synovium, 
tendon, and bursa 
chr7.14484502_A 4.15E-05 7.98E-01 
367.9 Blindness and low vision chr13.109829353_
A 
3.14E-05 8.00E-01 
596 Other disorders of bladder rs739677_A 4.38E-05 8.08E-01 
353 Nerve root and plexus disorders chr13.109783177_
G 
4.51E-06 8.18E-01 
686 Other local infections of skin 
and subcutaneous tissue 
chr9.135044095_G 3.69E-05 8.19E-01 
345.3 Convulsions chr11.2707861_A 2.12E-05 8.21E-01 
578.2 Blood in stool chr1.109570412_G 2.09E-05 8.36E-01 
227.3 Benign neoplasm of pituitary 
gland and craniopharyngeal 
duct (pouch) 
chr13.109840841_
A 
6.33E-06 8.48E-01 
272.11 Hypercholesterolemia chr6.25835361_A 3.42E-05 8.65E-01 
942 Infusion and transfusion 
reaction 
chr7.14266803_C 3.92E-05 8.85E-01 
275.6 Hypercalcemia chr11.2569137_A 3.17E-05 8.92E-01 
369 Infection of the eye chr6.26073531_G 1.16E-05 8.92E-01 
942 Infusion and transfusion 
reaction 
chr7.14271227_G 4.43E-05 8.94E-01 
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761 Cervicalgia chr1.160257615_G 2.82E-05 9.02E-01 
430.2 Intracerebral hemorrhage chr7.14702689_A 1.96E-05 9.19E-01 
743 Osteoporosis, osteopenia and 
pathological fracture 
chr6.25517293_G 3.36E-05 9.19E-01 
80 Postoperative infection chr6.26006590_G 3.55E-05 9.66E-01 
942 Infusion and transfusion 
reaction 
chr7.14271721_G 8.60E-06 9.76E-01 
362 Other retinal disorders chr6.25985598_A 4.82E-05 1.00E+00 
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